

National Lung Cancer Audit 2010



Prepared in partnership with:



The Healthcare Quality Improvement Partnership (HQIP) promotes quality in healthcare. HQIP holds commissioning and funding responsibility for the National Lung Cancer Audit and other national clinical audits as part of the National Clinical Audit & Patient Outcomes Programme (NCAPOP).



The NHS Information Centre for Health and Social Care (The NHS IC) is England's central, authoritative source of essential data and statistical information for frontline decision makers in health and social care. The NHS IC managed the publication of the 2010 annual report.



About the Royal College of Physicians; Clinical Effectiveness & Evaluation Unit

The Clinical Effectiveness and Evaluation unit (CEEu) of the Clinical Standards Department at the Royal College of Physicians runs a vibrant programme of projects that aim to improve the quality of health care in line with the best evidence for clinical practice: national comparative clinical audit, the measurement of clinical and patient outcomes, clinical change management and guideline development. The unit is self-funding, securing commissions and grants, often via competitive tendering processes, from numerous organisations including the Department of Health and charities such as the Health Foundation. Associate directors, who are practicing clinicians in their field, lead the relevant projects / programmes in conjunction with the CEEu clinical director and unit manager. All of our work is carried out in collaboration with relevant specialist societies, patient groups and National Health Service bodies.

National Lung Cancer Audit 2010

Report for the audit period 2009

Acknowledgements

The NLCA project team, Mick Peake, Paul Beckett, Ian Woolhouse and Roz Stanley would like to thank all the organisations that have made this report possible. These include The Health Quality Improvement Partnership (HQIP), The Royal College of Physicians (The RCP), The NHS Information Centre (The IC), NHS Connecting for Health (CFH), The University of Nottingham, The NLCA Clinical Reference Group, The Cancer Information System CYMRU (CANISC), Informing Healthcare (Wales), South East Scotland Cancer Network (SCAN), North of Scotland Cancer Network (NoSCAN) and West of Scotland Cancer Network (WoSCAN), The Northern Ireland Cancer Patient Pathway System (CaPPS), The Northern Ireland Cancer Network (NICaN) Lung Group, The Northern Ireland Cancer Registry (NICR), funded by The Northern Ireland Public Health Agency (PHA), Dr Luksza, Consultant Physician Jersey General Hospital, The Cancer Information Centre Southampton University Hospitals NHS Trust, The Oncology and Pathology departments Jersey General Hospital, and the Clinical Audit Officer Jersey General Hospital.

Thanks must also go to all the lung cancer teams who have contributed data to the audit as without their considerable efforts this report would not be possible. The NLCA project team have listened to the comments of service users concerning the previous annual reports, and as a result have produced this short report highlighting key issues. The team plan to publish more extensive analyses on the 2009 data, including case mix-adjusted data in an electronic format that can be more easily used by trusts. These data will be presented in a tabular format with minimal accompanying text, and will be available from the Information Centre website in due course.

Purpose of this report

The purpose of this document is to summarise the key finding of the National Lung Cancer Audit for patients diagnosed with lung cancer or mesothelioma who were first seen in 2009. Every trust in England and Wales, and every Health Board in Scotland has participated in the audit. The Scottish lung cancer dataset (excluding mesothelioma) has been collected for a number of years and this is the third year that the three Scottish networks have contributed data to the NLCA. Because of differences in reporting schedules, standards and targets the Scottish data are tabulated separately. Northern Ireland and Jersey have also participated in the audit for the first time this year, and similarly their data has been tabulated separately.

All data presented refers to cases submitted to the National Lung Cancer Audit unless otherwise stated.

Contents

Acknowledgements	04
Purpose of this report	04
Key messages	06
Recommendations	07
Summary detail of key findings	08
How many people were diagnosed with lung cancer	08
Figure 1 Number of patient records submitted to the NLCA England and Wales	08
Figure 2 Number of patient records submitted to the NLCA Scotland	08
Figure 3 Number of patient records submitted to the NLCA Northern Ireland	09
Figure 4 Number of patient records submitted to the NLCA Jersey	09
Figure 5 Case ascertainment England and Wales	10
Figure 6 Data completeness England and Wales	11
What is the standard of care given to patients?	11
Converting data into service improvement	11
The importance of the Lung Cancer Nurse Specialist	12
Trust performance	13
Handling of low case number	13
Data Groupings	13
Table 1a Data completeness for key fields England and Wales	13
Table 1b Data completeness for key fields Scotland	18
Table 1c Data completeness for key fields Northern Ireland	19
Table 1d Data completeness for key fields Jersey	19
Table 2a Process and clinical outcomes England and Wales	20
Table 2b Process and clinical outcomes Scotland	30
Table 2c Process and clinical outcomes Northern Ireland	30
Table 2d Process and clinical outcomes Jersey	31
Appendices	32
Appendix 1: Trust identification for England, Wales and Northern Ireland	33
Appendix 2: Local action plan	35
Appendix 3: Glossary	37

Key messages

- The audit has collected data on 37,637 patients in Great Britain and Northern Ireland for this audit period, representing approximately 95 per cent of the expected number of new lung cancer cases. With the exception of one hospital trust in Northern Ireland that did not participate in the audit this year because of incompleteness of the dataset and lack of validation of the existing data, this is thought to represent almost all cases of lung cancer presenting to secondary care.
- The quality of the submitted data has continued to improve and has exceeded that of 2008 (presented in the 2009 report), once again allowing detailed comparison of cancer networks and hospital trusts. Likewise, measures of care appear to have improved and whilst still below those reported from other Western European countries, the gap is narrowing.
- Despite these improvements, there remains variation across trusts and networks and differences in casemix do not appear to explain the whole of this variation. Poor data completeness in a few areas, especially where trusts fall at the lower extreme of these measures, may contribute to some of the variation seen.
- Although there is now evidence that the audit data is being used in many organisations to promote service improvement, there remains an urgent need for all Cancer Networks and Hospital Trusts to take responsibility for their data and use it to review and improve their local lung cancer services. This report contains a toolkit to help with this process.

1: Proportion of patients receiving a histological / cytological diagnosis

	England and Wales		Scotland		Northern Ireland		Jersey	
	2009	2008	2009	2008	2009	2008	2009	2008
Mean	75.6	72.2	77.7	77.5	70.8	n/a	90.6	n/a
Min	0.0	0.0	0.0	56.0	n/a	n/a	n/a	n/a
Lower Quartile	70.9	66.6	69.5	71.7	n/a	n/a	n/a	n/a
Median	77.5	73.3	76.1	78.5	n/a	n/a	n/a	n/a
Upper Quartile	85.2	82.1	81.4	82.1	n/a	n/a	n/a	n/a
Max	100.0	100.0	100.0	88.2	n/a	n/a	n/a	n/a

2: Proportion of patients receiving an operation

	England and Wales		Scotland		Northern Ireland		Jersey	
	2009	2008	2009	2008	2009	2008	2009	2008
Mean	13.7	10.8	11.3	10.6	13.4	n/a	9.4	n/a
Min	0.0	4.0	0.0	0.0	n/a	n/a	n/a	n/a
Lower Quartile	9.7	8.1	7.2	8.0	n/a	n/a	n/a	n/a
Median	12.4	9.6	10.0	10.5	n/a	n/a	n/a	n/a
Upper Quartile	16.1	12.7	11.5	12.0	n/a	n/a	n/a	n/a
Max	76.9	24.8	15.8	16.9	n/a	n/a	n/a	n/a

3: Proportion of patients receiving anti-cancer treatment

	England and Wales		Scotland		Northern Ireland		Jersey	
	2009	2008	2009	2008	2009	2008	2009	2008
Mean	59.1	54.0	64.6	64.1	64.7	n/a	71.9	n/a
Min	0.0	0.0	0.0	33.0	n/a	n/a	n/a	n/a
Lower Quartile	54.0	43.9	58.0	58.3	n/a	n/a	n/a	n/a
Median	60.5	54.1	62.4	62.2	n/a	n/a	n/a	n/a
Upper Quartile	66.5	61.6	69.2	67.3	n/a	n/a	n/a	n/a
Max	100.0	87.8	83.5	79.5	n/a	n/a	n/a	n/a

4: Proportion of patients receiving CT scan before bronchoscopy

	England and Wales		Scotland		Northern Ireland		Jersey	
	2009	2008	2009	2008	2009	2008	2009	2008
Mean	80.7	76.0	86.4	n/a	87.2	n/a	57.1	n/a
Min	0.0	0.0	0.0	n/a	n/a	n/a	n/a	n/a
Lower Quartile	74.2	64.5	81.3	n/a	n/a	n/a	n/a	n/a
Median	82.4	77.8	83.5	n/a	n/a	n/a	n/a	n/a
Upper Quartile	91.5	87.0	91.4	n/a	n/a	n/a	n/a	n/a
Max	100.0	100.0	99.3	n/a	n/a	n/a	n/a	n/a

Recommendations (England and Wales)

- All trusts should participate in this national audit
- Data on all patients diagnosed with either lung cancer or mesothelioma are submitted to the audit
- All relevant data fields are completed for each patient
- At least 85 per cent of patients should have stage and performance status recorded
- Over 95 per cent of patients submitted to the audit are discussed at a Multidisciplinary Team Meeting
- Histological/Cytological Confirmation rates below 75 per cent should be reviewed
- Over 80 per cent of patients are seen by a lung cancer specialist nurse
- Over 80 per cent of patients have a lung cancer specialist nurse present at the time of diagnosis (note that these data are not available for Wales)
- Surgical resection rates for NSCLC below the national average of 14 per cent should be reviewed
- Active anti-cancer treatment rates below the national average of 60 per cent should be reviewed
- Chemotherapy rates for small cell lung cancer below the national average of 65 per cent should be reviewed
- Chemotherapy rates for performance status 0-1stage IIIB / IV NSCLC lung cancer below the national average of 55 per cent should be reviewed
- Where CT scan prior to bronchoscopy rates are lower than 90 per cent, diagnostic pathways should be reviewed
- Trusts whose results in 2009 meet these recommendations should work to maintain their high standards and exceed them where appropriate

A local action planning toolkit is provided at the end of this document to assist organisations in benchmarking against these quality measures. It is important to stress that these quality measures are not targets, since in some cases there will be valid reasons for variation, such as case-mix and patient choice. All organisations are encouraged to use the audit data to drive their service development in order to improve the standard of care for lung cancer patients.

Scotland

Performance against these measures is highlighted by a system of colour-coding in the data tables. However these measures do not apply to Scotland and hence the data is not colour coded. NHS Quality Improvement Scotland published National Lung Cancer Standards in March 2008 which cover similar items to those noted above. For example, the Scottish standard for rate of histological / cytological diagnosis is set at a minimum of 75 per cent. Health boards in all Scottish networks will participate in comparing 2009 results measured against these standards.

Northern Ireland

Northern Ireland participated in the audit for the first time this year and in general follow the standards and Recommendations for England and Wales. Two issues were specifically noted:

- All Trusts in Northern Ireland should participate in subsequent audits.
- Access to clinical nurse specialists falls below the recommended target for England & Wales of 80 per cent and should be addressed.

Summary details of key findings

How many people were diagnosed with lung cancer?

In 2009 there were 32,547 patient records submitted from England and Wales (see Figure 1), 4,234 submitted from Scotland (figure 2), 819 submitted from Northern Ireland (figure 3) and 37 submitted from Jersey (figure 4). Combined, this is approximately 95 per cent of the annual incidence and probably almost all of those cases presenting to secondary care. 479 of these records were not suitable for further analysis (mainly from the English submissions) as there was no "date first seen" recorded, meaning that it was not possible to be certain that these were cases from 2009. Figures 1, 2, 3 & 4 show the incidence by cancer type. The Scottish data did not include cases of mesothelioma in 2009.

Figure 1
Number of patient records submitted to the NLCA – England and Wales




Figure 2
Number of patient records submitted to the NLCA – Scotland




Figure 3
Number of patient records submitted to the NLCA – Northern Ireland






Figure 4
Number of patient records submitted to the NLCA – Jersey



There has been a year on year increase in submissions from a baseline of 12,784 (40 per cent of expected - originally England only) in 2005 as shown in figure 5. In Scotland overall case ascertainment has risen slightly from 88 per cent last year.

Figure 5
Case ascertainment England and Wales

* England only ** England and Wales



How accurate are the data in this report?

Data submitted to the National Lung Cancer Audit need to be as complete as possible in terms of healthcare organisation participation, population coverage and data field completeness both to ensure the representative nature of the information and to make case-mix adjustment possible. Please refer to previous versions of the Annual Report for a full explanation of this issue.

All Networks, Trusts or Health boards in England, Wales and Scotland have participated in the audit. Jersey has also fully participated in the audit. One Hospital Trust in Northern Ireland was unable to participate in this year's audit.

As can be seen from [figure 5](#), the audit has captured almost all the cases of lung cancer and mesothelioma presenting to secondary care. This probably represents around 95 per cent of the total number of cases in England and Wales. The "Data Completeness" section in [Table 1a](#) shows the number of cases and per cent of expected cases (based on historic cancer registry returns) submitted by Network and by Trust (key to codes given in the Appendix 1) across England and Wales. [Table 1b](#) shows similar data for Scottish networks, [1c](#) for Northern Ireland and [1d](#) for Jersey. Similarly these tables indicate the data completeness for the key non-mandatory fields of Stage and Performance Status (PS) and the data completeness for the MDT discussion indicator and for the recording of treatment. Comparison with previous years ([figure 6](#) for England and Wales) shows that data field completeness continues to improve. In Scotland, data completeness for MDT discussion shows improvement rising from 89.9 per cent to 97.4 per cent, and data completeness for both stage and P.S has also improved.

Figure 6
Key data field completeness by year



What is the standard of care given to patients?

Table 2a lists headline indicators (Process, Specialist Nursing, Imaging and Outcome for England and Wales) by Network and by Trust (key to codes given in the Appendix 1) for all lung cancer and mesothelioma cases across England and Wales. These indicators have been chosen to reflect the overall standard of care provided to patients. In interpreting these figures, the above caveats regarding data completeness referred to previously must be borne in mind. Furthermore, the results as presented do not take into account the case-mix of patients. Adjustments to the results to account for case-mix will be available from the Information Centre website in due course. National variation is still apparent even after case-mix adjustment, although it is less pronounced. However, for individual organisations it may make a particular indicator move from appearing abnormally high/low, to being in line with national averages.

The colour coding reflects the recommendations set in the 2008 Local Action Plan (LAP) and gives an overall picture of how a trust or network is performing against these recommendations. Note that for case ascertainment (per cent

of expected), to achieve green status over 75 per cent of the expected number of cases must have been submitted, trusts attaining 50 – 75 per cent are coded amber whilst trusts submitting less than 50 per cent of the expected number are coded red. Trusts with a high tertiary workload or where the recommendations are known to not be applicable for other reasons are shown in blue throughout. Many of the trusts in this category fully participate in the audit by submitting treatment data for other trusts. However their full contribution to the audit process may not be reflected by the way these audit data are presented.

Similar data for Scotland is shown in table 2b. Local Action Plan recommendations do not apply to Scotland; hence the data are not colour coded. National Lung Cancer Standards published by NHS Quality Improvement Scotland in 2008 include standards for rate of histological confirmation (minimum 75per cent) and percentage SCLC having chemotherapy (minimum 60 per cent) but do not specify rates of resection or anti-cancer treatment.

Data for Northern Ireland and Jersey are shown in tables 2c and 2d respectively.

Converting data in to service improvement

Collecting data is only part of the audit process and it is important that the data is used to improve the services provided to patients and the outcomes of their treatment. There are numerous examples of local organisations doing just this and an example is given below. Furthermore, national organisations such as the National Institute for Health and Clinical Excellence, the British Thoracic Society and the National Cancer Peer Review Programme have all utilised data from the audit in their work programmes for lung cancer.

The improving lung cancer outcomes project (ILCOP) has been funded by the Health Foundation with the aim of using the NLCA results, together with a new patient experience survey, to drive improvements at a local level by pairing 30 trusts within England whom have undergone facilitated peer review visits to share good practice, followed by a programme of facilitated quality improvement. The impact will be assessed using NLCA headline indicator data and a follow up patient experience survey.

The Lung Cancer Nurse Specialist

Data from the National Lung Cancer Audit shows that patients seen by a lung cancer nurse specialist (LCNS) were more likely to receive anti-cancer treatment compared to those that were not seen or those where no data is recorded and hence it is not known whether these patients saw a LCNS.

This table shows that 64.8 per cent of patients seen by a LCNS received anti-cancer treatment compared to 30.4 per cent of those who were not seen by the LCNS. For patients where it was not known whether or not they were seen by a LCNS 52.6 per cent received active treatment.

Whilst this is an interesting finding that highlights the importance of the LCNS, further work is needed to explain this observation.

Proportion of patients seen by a LCNS receiving active treatment

	2009	2008
Seen by LCNS	64.8%	59.4%
Data not recorded	52.6%	51.0%
Not seen by LCNS	30.4%	30.6%

Trust performance

Handling of low case numbers

It should be noted that trusts submitting very low numbers of cases with high levels of data completeness have been omitted from the tables below to ensure that no details about specific patients can be identified in this report. Because of this, network totals may not equal the sum of the composite trusts. For example, in a trust with only two submitted cases of lung cancer, with 100 per cent data completeness and a resection rate of 100 per cent, it would be possible to know the details of treatment of all lung cancer patients seen at that trust. However in most cases, each reported value is composed of multiple variables so it is impossible to surmise information about specific individuals from this report.

Data groupings

England and Wales

For England and Wales, Northern Ireland and Jersey the data has been divided into 4 groups for analysis:-

- All cases of lung cancer submitted to the audit (this includes lung cancer and mesothelioma). This is the default grouping on which all analyses have been carried out unless otherwise specified.
- NSCLC – non-small cell lung cancer or, more correctly this should be considered NOT small cell lung cancer. This group includes all lung cancers including those that are clinically diagnosed, but excludes pathological diagnoses of small cell lung cancer, and clinical or pathological diagnoses of mesothelioma.

- Histologically confirmed non-small cell lung cancer – all cases of non-small cell lung cancer that are confirmed by a histological or cytological specimen.
- Small cell lung cancer – all cases of lung cancer that are confirmed to be of small cell type by a histological or cytological specimen.

This year a new indicator has been reported. “percentage pretreatment NSCLC histology NOS” is the proportion of histologically/cytologically confirmed cases of NSCLC where the diagnosis is given as Non-Small Cell Carcinoma Not Otherwise Specified, rather than a subtype of NSCLC such as adenocarcinoma or squamous carcinoma. A low NOS rate may be important since selection of treatment may be dependent upon such subclassification.

For the analyses in Scotland the groupings are slightly different as mesothelioma cases are not included in the current audit data (collection of Mesothelioma data in Scotland started in January 2010). The two groupings used were:

- All cases of lung cancer submitted to the audit (this includes lung cancer but excludes mesothelioma). This is the default grouping on which all Scottish analyses have been carried out unless otherwise specified.
- Small cell lung cancer – all cases of lung cancer that are confirmed to be of small cell type by a histological or cytological specimen.

Table 1a
Data completeness for key fields England and Wales

Code	Expected number	Actual Number	% of expected	MDT Completeness (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS & Stage Completeness (%)	Treatment Recorded (%)	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at diagnosis (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)
N01	989	1034	105 ●	93.3 ▲	61.6 ▲	84.1 ●	55.0 ▲	93.1 ●	56.2 ▲	48.1 ▲	93.4 ●	70.2 ▲
RTX	184	219	119 ●	95.0 ▲	37.0 ▲	75.8 ●	30.6 ▲	85.4 ●	27.4 ▲	21.0 ▲	88.6 ●	49.8 ▲
RXL	242	251	104 ●	86.5 ▲	93.2 ●	82.9 ●	80.5 ●	97.6 ●	94.4 ●	73.3 ▲	96.8 ●	78.5 ●
RXN	136	223	164 ●	96.4 ●	62.8 ▲	87.4 ●	58.7 ▲	92.8 ●	79.8 ●	76.2 ●	96.0 ●	66.4 ▲
RXR	427	341	80 ●	95.3 ●	53.4 ▲	88.3 ●	49.6 ▲	95.0 ●	31.1 ▲	28.4 ▲	92.4 ●	79.8 ●
N02	2134	2125	100 ●	82.6 ▲	71.9 ▲	72.5 ▲	60.8 ▲	80.0 ●	50.4 ▲	36.8 ▲	88.2 ●	68.7 ▲
RBT	116	67	58 ■	28.4 ▲	25.4 ▲	41.8 ▲	22.4 ▲	95.5 ●	17.9 ▲	11.9 ▲	23.9 ▲	22.4 ▲
RBV	165	47	28 ◆	12.8 ◆	36.2 ◆	34.0 ◆	29.8 ◆	80.9 ◆	29.8 ◆	14.9 ◆	38.3 ◆	27.7 ◆
RJN	89	100	112 ●	97.0 ●	97.0 ●	80.0 ●	79.0 ●	95.0 ●	97.0 ●	93.0 ●	98.0 ●	83.0 ●
RM2	321	211	66 ◆	55.9 ◆	33.2 ◆	53.1 ◆	23.2 ◆	80.1 ◆	14.7 ◆	13.3 ◆	68.2 ◆	40.8 ◆
RM3	135	215	159 ●	73.0 ▲	73.0 ▲	71.6 ▲	56.7 ▲	68.4 ▲	82.3 ●	62.8 ▲	95.8 ●	41.4 ▲
RM4	89	92	103 ●	100.0 ●	98.9 ●	100.0 ●	98.9 ●	89.1 ●	100.0 ●	95.7 ●	100.0 ●	97.8 ●
RMC	196	217	111 ●	98.6 ●	95.4 ●	99.5 ●	95.4 ●	86.6 ●	92.2 ●	65.9 ▲	99.1 ●	99.1 ●
RMP	130	149	115 ●	98.7 ●	65.1 ▲	75.8 ●	53.7 ▲	98.0 ●	89.9 ●	51.0 ▲	98.0 ●	98.0 ●
RRF	161	196	122 ●	72.4 ▲	29.6 ▲	43.4 ▲	21.4 ▲	50.5 ▲	34.2 ▲	1.0 ▲	93.4 ●	43.4 ▲
RW3	103	120	117 ●	87.5 ▲	85.8 ●	59.2 ▲	56.7 ▲	89.2 ●	82.5 ●	60.0 ▲	95.0 ●	97.5 ●
RW6	524	569	109 ●	92.8 ▲	86.8 ●	78.4 ●	72.8 ▲	88.8 ●	2.3 ▲	1.9 ▲	89.3 ●	72.1 ▲
RWJ	105	142	135 ●	92.3 ▲	83.8 ●	89.4 ●	78.9 ●	43.0 ▲	95.8 ●	83.8 ●	94.4 ●	78.2 ●

Table 1a (continued)

Data completeness for key fields England and Wales

Code	Expected number	Actual Number	% of expected	MDT Completeness (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS & Stage Completeness (%)	Treatment Recorded (%)	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at diagnosis (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)
N03	1535	1827	119 ●	98.8 ●	87.5 ●	91.0 ●	80.8 ●	79.3 ●	84.7 ●	68.3 ▲	97.6 ●	73.9 ▲
RBL	119	321	270 ●	97.5 ●	86.3 ●	99.4 ●	85.7 ●	75.7 ●	96.6 ●	86.0 ●	97.8 ●	97.5 ●
RBN	221	221	100 ●	100.0 ●	96.4 ●	93.7 ●	92.3 ●	88.7 ●	61.5 ▲	61.5 ▲	96.8 ●	64.3 ▲
RBQ	212	238	112 ●	100.0 ●	95.4 ●	95.4 ●	91.2 ●	67.2 ▲	94.1 ●	92.9 ●	99.2 ●	98.7 ●
REM	323	335	104 ●	97.9 ●	86.9 ●	82.4 ●	73.4 ▲	86.6 ●	75.5 ●	21.2 ▲	98.2 ●	60.0 ▲
REN	48	1	2 ◆	100.0 ◆	100.0 ◆	100.0 ◆	100.0 ◆	100.0 ◆	0.0 ◆	0.0 ◆	100.0 ◆	0.0 ◆
RJR	121	209	173 ●	100.0 ●	74.6 ▲	91.4 ●	69.4 ▲	90.4 ●	72.2 ▲	72.2 ▲	94.3 ●	41.1 ▲
RQ6	216	147	68 ■	98.0 ●	98.6 ●	86.4 ●	85.0 ●	78.9 ●	93.2 ●	70.1 ▲	97.3 ●	61.9 ▲
RVY	82	157	191 ●	100.0 ●	85.4 ●	93.0 ●	80.3 ●	97.5 ●	94.9 ●	94.9 ●	98.7 ●	59.9 ▲
RWW	193	198	103 ●	98.0 ●	77.8 ●	84.8 ●	69.7 ▲	50.5 ▲	94.9 ●	70.7 ▲	98.0 ●	94.9 ●
N06	1811	1857	103 ●	99.2 ●	85.1 ●	79.0 ●	68.5 ▲	92.4 ●	95.4 ●	50.5 ▲	99.6 ●	98.8 ●
RAE	240	204	85 ●	100.0 ●	64.2 ▲	98.5 ●	63.2 ▲	100.0 ●	95.6 ●	86.3 ●	100.0 ●	100.0 ●
RCB	173	169	98 ●	96.4 ●	94.7 ●	70.4 ▲	66.9 ▲	93.5 ●	100.0 ●	68.6 ▲	100.0 ●	100.0 ●
RCD	91	95	104 ●	94.7 ▲	91.6 ●	94.7 ●	90.5 ●	80.0 ●	88.4 ●	60.0 ▲	95.8 ●	91.6 ●
RCF	118	93	79 ●	100.0 ●	100.0 ●	97.8 ●	97.8 ●	95.7 ●	97.8 ●	76.3 ●	100.0 ●	100.0 ●
RR8	565	553	98 ●	100.0 ●	99.1 ●	88.4 ●	88.1 ●	92.2 ●	99.8 ●	0.0 ▲	100.0 ●	100.0 ●
RWY	244	278	114 ●	100.0 ●	50.4 ▲	79.9 ●	45.0 ▲	97.5 ●	98.9 ●	71.6 ▲	99.6 ●	99.3 ●
RXF	380	465	122 ●	99.1 ●	90.5 ●	54.8 ▲	51.8 ▲	87.5 ●	87.1 ●	68.4 ▲	99.4 ●	97.2 ●
N07	753	782	104 ●	99.1 ●	93.6 ●	86.1 ●	82.5 ●	94.8 ●	76.5 ●	48.8 ▲	98.6 ●	97.3 ●
RCC	126	147	117 ●	100.0 ●	95.9 ●	91.2 ●	89.1 ●	91.8 ●	99.3 ●	92.5 ●	100.0 ●	100.0 ●
RJL	226	249	110 ●	97.2 ●	82.7 ●	80.3 ●	70.7 ▲	96.0 ●	85.5 ●	78.3 ●	98.0 ●	91.6 ●
RWA	401	386	96 ●	100.0 ●	99.7 ●	87.8 ●	87.6 ●	95.1 ●	61.9 ▲	13.2 ▲	98.4 ●	100.0 ●
N08	1246	1391	112 ●	99.1 ●	95.8 ●	89.8 ●	87.0 ●	94.8 ●	28.7 ▲	19.7 ▲	97.4 ●	83.7 ●
RFF	131	169	129 ●	95.3 ●	83.4 ●	83.4 ●	72.8 ▲	96.4 ●	84.6 ●	82.2 ●	93.5 ●	92.3 ●
RFR	144	160	111 ●	100.0 ●	99.4 ●	96.9 ●	96.3 ●	94.4 ●	77.5 ●	69.4 ▲	100.0 ●	100.0 ●
RFS	174	205	118 ●	100.0 ●	98.5 ●	76.6 ●	75.1 ●	99.0 ●	58.0 ▲	6.8 ▲	95.1 ●	100.0 ●
RHQ	480	453	94 ●	99.6 ●	99.6 ●	98.0 ●	97.8 ●	93.6 ●	2.2 ▲	1.8 ▲	98.9 ●	98.7 ●
RP5	317	404	127 ●	99.5 ●	93.8 ●	87.1 ●	83.2 ●	93.3 ●	0.7 ▲	0.5 ▲	97.5 ●	48.5 ▲
N11	1066	1159	109 ●	97.0 ●	90.2 ●	94.3 ●	87.1 ●	95.7 ●	60.5 ▲	48.1 ▲	96.2 ●	71.8 ▲
RBK	158	136	86 ●	94.9 ▲	88.2 ●	94.9 ●	85.3 ●	97.8 ●	86.0 ●	83.1 ●	91.2 ●	77.9 ●
RR1	404	460	114 ●	94.8 ▲	93.9 ●	93.5 ●	91.1 ●	91.3 ●	30.9 ▲	27.8 ▲	96.5 ●	78.0 ●
RRK	245	261	107 ●	100.0 ●	98.1 ●	99.2 ●	97.7 ●	98.5 ●	86.6 ●	86.6 ●	99.2 ●	55.6 ▲
RXK	259	300	116 ●	99.3 ●	79.0 ●	91.7 ●	73.3 ▲	99.0 ●	71.7 ▲	29.7 ▲	96.0 ●	74.0 ▲
N12	414	517	125 ●	99.4 ●	79.7 ●	73.9 ▲	64.8 ▲	89.4 ●	82.8 ●	65.4 ▲	95.7 ●	92.5 ●
RJC	5	96	1920 ●	99.0 ●	97.9 ●	58.3 ▲	57.3 ▲	79.2 ●	100.0 ●	92.7 ●	99.0 ●	100.0 ●
RKB	249	218	88 ●	100.0 ●	91.3 ●	85.3 ●	77.5 ●	97.2 ●	89.9 ●	64.7 ▲	100.0 ●	99.5 ●
RLT	96	127	132 ●	100.0 ●	91.3 ●	92.1 ●	85.8 ●	86.6 ●	92.9 ●	71.7 ▲	100.0 ●	99.2 ●
RWP00	64	76	119 ●	97.4 ●	3.9 ▲	30.3 ▲	2.6 ▲	84.2 ●	23.7 ▲	22.4 ▲	72.4 ▲	51.3 ▲
N20	532	538	101 ●	98.7 ●	79.2 ●	71.7 ▲	60.8 ▲	94.8 ●	81.8 ●	71.0 ▲	95.0 ●	78.1 ●
RC9	109	143	131 ●	98.6 ●	91.6 ●	74.1 ▲	70.6 ▲	95.1 ●	90.9 ●	76.9 ●	99.3 ●	86.0 ●
RWG	217	173	80 ●	97.7 ●	53.8 ▲	76.3 ●	47.4 ▲	91.9 ●	62.4 ▲	46.2 ▲	85.5 ●	43.9 ▲
RWH	206	222	108 ●	99.5 ●	91.0 ●	66.7 ▲	64.9 ▲	96.8 ●	91.0 ●	86.5 ●	99.5 ●	99.5 ●

Table 1a (continued)

Data completeness for key fields England and Wales

Code	Expected number	Actual Number	% of expected	MDT Completeness (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS & Stage Completeness (%)	Treatment Recorded (%)	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at diagnosis (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)
N21	862	666	77 ●	98.6 ●	90.4 ●	88.1 ●	82.4 ●	84.7 ●	95.3 ●	72.1 ▲	96.7 ●	85.6 ●
RAS	100	135	135 ●	99.3 ●	99.3 ●	88.1 ●	88.1 ●	60.0 ▲	98.5 ●	94.8 ●	98.5 ●	97.8 ●
RC3	75	62	83 ●	98.4 ●	96.8 ●	96.8 ●	95.2 ●	91.9 ●	98.4 ●	72.6 ▲	100.0 ●	98.4 ●
RFW	70	90	129 ●	98.9 ●	97.8 ●	100.0 ●	97.8 ●	96.7 ●	98.9 ●	0.0 ▲	98.9 ●	98.9 ●
RQM	80	60	75 ■	100.0 ●	100.0 ●	93.3 ●	93.3 ●	90.0 ●	98.3 ●	75.0 ▲	100.0 ●	100.0 ●
RT3	148	13	9 ◆	84.6 ◆	7.7 ◆	46.2 ◆	0.0 ◆	100.0 ◆	69.2 ◆	38.5 ◆	15.4 ◆	15.4 ◆
RV8	100	83	83 ●	97.6 ●	72.3 ▲	89.2 ●	68.7 ▲	91.6 ●	84.3 ●	75.9 ●	97.6 ●	67.5 ▲
RYJ	289	223	77 ●	99.1 ●	89.2 ●	81.6 ●	76.2 ●	87.9 ●	96.0 ●	87.0 ●	97.3 ●	76.2 ●
N22	732	733	100 ●	99.0 ●	94.8 ●	92.4 ●	89.4 ●	90.9 ●	95.6 ●	85.4 ●	91.3 ●	90.2 ●
RAL	86	87	101 ●	100.0 ●	100.0 ●	100.0 ●	100.0 ●	100.0 ●	100.0 ●	97.7 ●	100.0 ●	97.7 ●
RAP	84	89	106 ●	100.0 ●	100.0 ●	93.3 ●	93.3 ●	80.9 ●	98.9 ●	95.5 ●	100.0 ●	100.0 ●
RKE	98	79	81 ●	100.0 ●	88.6 ●	98.7 ●	88.6 ●	87.3 ●	84.8 ●	69.6 ▲	100.0 ●	100.0 ●
RQW	113	152	135 ●	98.7 ●	92.1 ●	81.6 ●	79.6 ●	88.2 ●	94.1 ●	80.3 ●	95.4 ●	95.4 ●
RRV	139	115	83 ●	99.1 ●	94.8 ●	96.5 ●	93.0 ●	94.8 ●	93.9 ●	80.0 ●	52.2 ▲	50.4 ▲
RVL	212	211	100 ●	98.1 ●	94.8 ●	91.9 ●	88.6 ●	92.4 ●	98.6 ●	88.6 ●	99.1 ●	97.2 ●
N23	780	770	99 ●	93.5 ▲	62.1 ▲	73.0 ▲	52.2 ▲	84.9 ●	74.2 ▲	55.6 ▲	91.0 ●	84.7 ●
RF4	340	314	92 ●	92.7 ▲	51.0 ▲	63.7 ▲	36.9 ▲	81.5 ●	70.4 ▲	45.5 ▲	91.7 ●	89.8 ●
RGC	115	127	110 ●	95.3 ●	91.3 ●	86.6 ●	84.3 ●	88.2 ●	93.7 ●	88.2 ●	94.5 ●	93.7 ●
RNH	115	116	101 ●	94.0 ▲	78.4 ●	82.8 ●	68.1 ▲	81.9 ●	79.3 ●	46.6 ▲	94.8 ●	94.8 ●
RNJ	110	102	93 ●	91.2 ▲	17.6 ▲	58.8 ▲	12.7 ▲	93.1 ●	37.3 ▲	17.6 ▲	76.5 ●	34.3 ▲
RQX	100	111	111 ●	95.5 ●	83.8 ●	86.5 ●	78.4 ●	86.5 ●	91.0 ●	91.0 ●	94.6 ●	95.5 ●
N24	873	803	92 ●	91.2 ▲	76.5 ●	73.2 ▲	64.1 ▲	83.2 ●	73.7 ▲	62.9 ▲	89.5 ●	54.7 ▲
RJ1	273	154	56 ■	99.4 ●	72.7 ▲	91.6 ●	68.2 ▲	100.0 ●	91.6 ●	64.3 ▲	100.0 ●	98.7 ●
RJ2	116	93	80 ●	50.5 ▲	40.9 ▲	49.5 ▲	29.0 ▲	79.6 ●	1.1 ▲	1.1 ▲	97.8 ●	95.7 ●
RJZ	114	131	115 ●	100.0 ●	96.9 ●	91.6 ●	91.6 ●	67.2 ▲	100.0 ●	99.2 ●	100.0 ●	0.8 ▲
RYQ	370	425	115 ●	94.4 ▲	79.3 ●	66.1 ▲	61.9 ▲	82.8 ●	75.1 ●	64.7 ▲	80.7 ●	46.4 ▲
N25	785	587	75 ■	89.8 ▲	55.9 ▲	62.5 ▲	46.7 ▲	80.9 ●	25.2 ▲	21.3 ▲	66.4 ▲	36.1 ▲
RAX	159	90	57 ■	86.7 ▲	43.3 ▲	78.9 ●	40.0 ▲	78.9 ●	75.6 ●	65.6 ▲	93.3 ●	27.8 ▲
RJ6	132	104	79 ●	96.2 ●	91.3 ●	82.7 ●	78.8 ●	85.6 ●	74.0 ▲	61.5 ▲	88.5 ●	34.6 ▲
RJ7	239	157	66 ■	89.2 ▲	56.7 ▲	64.3 ▲	42.0 ▲	92.4 ●	1.3 ▲	1.3 ▲	5.7 ▲	1.3 ▲
RPY	0	13	0 ◆	0.0 ◆	46.2 ◆	53.8 ◆	30.8 ◆	84.6 ◆	7.7 ◆	0.0 ◆	0.0 ◆	0.0 ◆
RVR	245	223	91 ●	93.7 ▲	44.4 ▲	45.7 ▲	38.6 ▲	71.3 ▲	0.0 ▲	0.0 ▲	91.9 ▲	66.8 ▲
N26	920	1069	116 ●	97.8 ●	77.5 ●	85.2 ●	69.1 ▲	95.9 ●	96.3 ●	81.7 ●	98.8 ●	92.7 ●
RA9	156	188	121 ●	99.5 ●	97.3 ●	98.9 ●	97.3 ●	95.2 ●	98.9 ●	92.6 ●	100.0 ●	97.9 ●
RBZ	85	95	112 ●	98.9 ●	78.9 ●	72.6 ▲	57.9 ▲	95.8 ●	98.9 ●	86.3 ●	90.5 ●	40.0 ▲
REF	223	286	128 ●	92.7 ▲	55.9 ▲	70.6 ▲	44.8 ▲	93.7 ●	94.4 ●	87.4 ●	99.7 ●	96.9 ●
RH8	200	193	97 ●	100.0 ●	85.5 ●	83.9 ●	72.0 ▲	97.4 ●	89.6 ●	78.2 ●	98.4 ●	98.4 ●
RK9	256	307	120 ●	100.0 ●	79.8 ●	95.1 ●	76.2 ●	97.4 ●	99.7 ●	70.4 ▲	100.0 ●	98.4 ●
N27	402	467	116 ●	99.8 ●	87.8 ●	74.7 ▲	68.3 ▲	91.6 ●	97.4 ●	85.4 ●	98.9 ●	83.3 ●
RBD	82	120	146 ●	100.0 ●	60.8 ▲	70.0 ▲	49.2 ▲	90.8 ●	100.0 ●	91.7 ●	99.2 ●	98.3 ●
RD3	150	141	94 ●	100.0 ●	100.0 ●	76.6 ●	76.6 ●	94.3 ●	93.6 ●	66.7 ▲	99.3 ●	48.2 ▲
RDZ	170	206	121 ●	99.5 ●	95.1 ●	76.2 ●	73.8 ▲	90.3 ●	98.5 ●	94.7 ●	98.5 ●	98.5 ●

Table 1a (continued)

Data completeness for key fields England and Wales

Code	Expected number	Actual Number	% of expected	MDT Completeness (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS & Stage Completeness (%)	Treatment Recorded (%)	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at diagnosis (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)
N28	843	846	100 ●	92.6 ▲	44.2 ▲	73.3 ▲	38.9 ▲	89.7 ●	47.0 ▲	46.8 ▲	87.1 ●	54.8 ▲
RA3	82	92	112 ●	77.2 ▲	96.7 ●	94.6 ●	91.3 ●	91.3 ●	58.7 ▲	56.5 ▲	83.7 ●	48.9 ▲
RA4	62	79	127 ●	81.0 ▲	70.9 ▲	55.7 ▲	40.5 ▲	83.5 ●	27.8 ▲	27.8 ▲	89.9 ●	41.8 ▲
RA7	180	136	76 ●	97.8 ●	4.4 ▲	35.3 ▲	4.4 ▲	87.5 ●	57.4 ▲	57.4 ▲	60.3 ▲	33.8 ▲
RBA	121	180	149 ●	94.4 ▲	96.7 ●	93.3 ●	92.2 ●	90.6 ●	57.8 ▲	57.8 ▲	99.4 ●	76.1 ●
RD1	170	145	85 ●	91.7 ▲	0.0 ▲	58.6 ▲	0.0 ▲	92.4 ●	79.3 ●	79.3 ●	89.0 ●	66.2 ▲
RVJ	228	214	94 ●	99.1 ●	22.9 ▲	87.9 ●	19.2 ▲	90.2 ●	11.7 ▲	11.7 ▲	93.0 ●	50.0 ▲
N29	437	533	122 ●	97.2 ●	82.2 ●	80.1 ●	70.2 ▲	87.1 ●	72.4 ▲	49.2 ▲	94.9 ●	90.6 ●
RLQ	74	112	151 ●	100.0 ●	93.8 ●	91.1 ●	88.4 ●	90.2 ●	98.2 ●	67.9 ▲	100.0 ●	100.0 ●
RTE	244	282	116 ●	98.2 ●	83.7 ●	83.0 ●	69.9 ▲	87.2 ●	97.2 ●	65.6 ▲	94.3 ●	99.3 ●
RWP50	119	139	117 ●	92.8 ▲	69.8 ▲	65.5 ▲	56.1 ▲	84.2 ●	1.4 ▲	0.7 ▲	92.1 ●	65.5 ▲
N30	1031	1205	117 ●	98.4 ●	85.6 ●	74.2 ▲	70.5 ▲	86.2 ●	63.9 ▲	59.6 ▲	78.0 ●	50.2 ▲
RD7	112	150	134 ●	98.7 ●	34.7 ▲	5.3 ▲	2.0 ▲	59.3 ▲	0.0 ▲	0.0 ▲	0.0 ▲	0.0 ▲
RD8	96	115	120 ●	96.5 ●	85.2 ●	73.9 ▲	67.0 ▲	87.8 ●	74.8 ▲	73.9 ▲	79.1 ●	67.8 ▲
RHW	206	193	94 ●	100.0 ●	90.2 ●	91.2 ●	82.9 ●	98.4 ●	99.5 ●	90.7 ●	100.0 ●	99.5 ●
RN3	113	155	137 ●	99.4 ●	94.8 ●	92.3 ●	89.7 ●	83.9 ●	61.9 ▲	61.9 ▲	91.6 ●	40.0 ▲
RTH	303	387	128 ●	97.9 ●	94.3 ●	81.7 ●	79.8 ●	87.3 ●	72.9 ▲	72.1 ▲	94.8 ●	39.3 ▲
RXQ	201	202	100 ●	98.0 ●	95.5 ●	80.7 ●	78.7 ●	93.1 ●	55.0 ▲	39.6 ▲	71.3 ▲	58.9 ▲
N31	1092	1068	98 ●	97.0 ●	71.1 ▲	79.4 ●	60.0 ▲	89.5 ●	72.4 ▲	41.7 ▲	71.8 ▲	62.3 ▲
RHM	448	262	58 ■	90.8 ▲	57.3 ▲	82.1 ●	52.3 ▲	95.8 ●	33.2 ▲	26.0 ▲	85.9 ●	84.7 ●
RHU	279	261	94 ●	98.9 ●	55.9 ▲	69.7 ▲	37.2 ▲	80.1 ●	78.5 ●	0.4 ▲	4.6 ▲	0.8 ▲
RN1	94	96	102 ●	99.0 ●	60.4 ▲	45.8 ▲	30.2 ▲	84.4 ●	49.0 ▲	37.5 ▲	97.9 ●	69.8 ▲
RN5	39	87	223 ●	97.7 ●	64.4 ▲	71.3 ▲	50.6 ▲	98.9 ●	96.6 ●	64.4 ▲	98.9 ●	98.9 ●
RNZ	71	101	142 ●	99.0 ●	98.0 ●	94.1 ●	93.1 ●	95.0 ●	96.0 ●	84.2 ●	97.0 ●	93.1 ●
RR2	53	104	196 ●	99.0 ●	93.3 ●	94.2 ●	88.5 ●	93.3 ●	99.0 ●	96.2 ●	99.0 ●	99.0 ●
RYR	108	156	144 ●	100.0 ●	97.4 ●	96.8 ●	94.2 ●	87.2 ●	95.5 ●	63.5 ▲	94.9 ●	58.3 ▲
N32	540	613	114 ●	92.2 ▲	71.6 ▲	80.4 ●	65.6 ▲	92.5 ●	67.4 ▲	66.2 ▲	94.5 ●	66.7 ▲
RA2	109	75	69 ■	78.7 ▲	4.0 ▲	44.0 ▲	4.0 ▲	90.7 ●	34.7 ▲	32.0 ▲	94.7 ●	65.3 ▲
RDU	116	156	134 ●	93.6 ▲	76.9 ●	82.7 ●	67.9 ▲	94.9 ●	74.4 ▲	74.4 ▲	91.7 ●	48.1 ▲
RTK	159	186	117 ●	91.4 ▲	73.1 ▲	88.7 ●	73.1 ▲	95.2 ●	61.8 ▲	59.1 ▲	94.6 ●	93.0 ●
RTP	156	195	125 ●	96.9 ●	92.3 ●	85.1 ●	80.5 ●	89.2 ●	80.0 ●	80.0 ●	96.4 ●	56.9 ▲
N33	620	638	103 ●	99.8 ●	90.8 ●	84.5 ●	77.9 ●	90.3 ●	72.7 ▲	72.7 ▲	95.1 ●	54.5 ▲
RPL	140	161	115 ●	100.0 ●	91.9 ●	71.4 ▲	66.5 ▲	92.5 ●	88.2 ●	88.2 ●	93.8 ●	58.4 ▲
RXC	229	270	118 ●	99.6 ●	93.0 ●	88.5 ●	83.0 ●	96.7 ●	74.8 ▲	74.8 ▲	97.0 ●	55.2 ▲
RXH	251	207	82 ●	100.0 ●	87.0 ●	89.4 ●	80.2 ●	80.2 ●	58.0 ▲	58.0 ▲	93.7 ●	50.7 ▲
N34	903	748	83 ●	87.6 ▲	61.5 ▲	82.2 ●	58.4 ▲	89.2 ●	14.0 ▲	11.9 ▲	30.2 ▲	13.9 ▲
RN7	121	103	85 ●	100.0 ●	100.0 ●	77.7 ●	77.7 ●	100.0 ●	99.0 ●	83.5 ●	100.0 ●	99.0 ●
RPA	205	81	40 ▲	4.9 ▲	0.0 ▲	61.7 ▲	0.0 ▲	2.5 ▲	0.0 ▲	0.0 ▲	0.0 ▲	0.0 ▲
RVV	374	370	99 ●	96.2 ●	95.7 ●	99.2 ●	95.7 ●	99.5 ●	0.0 ▲	0.0 ▲	0.0 ▲	0.0 ▲
RWF	203	194	96 ●	99.0 ●	1.5 ▲	60.8 ▲	1.5 ▲	100.0 ●	1.5 ▲	1.5 ▲	63.4 ▲	1.0 ▲
N35	1105	1022	92 ●	94.3 ▲	49.9 ▲	55.9 ▲	44.0 ▲	85.1 ●	52.4 ▲	50.5 ▲	92.6 ●	67.7 ▲
RJD	160	167	104 ●	99.4 ●	98.8 ●	89.2 ●	88.6 ●	89.2 ●	99.4 ●	95.2 ●	100.0 ●	93.4 ●
RJE	345	250	72 ■	92.8 ▲	28.8 ▲	50.4 ▲	27.6 ▲	89.6 ●	57.2 ▲	55.6 ▲	95.6 ●	65.2 ▲
RL4	189	207	110 ●	100.0 ●	100.0 ●	92.3 ●	92.3 ●	95.2 ●	93.2 ●	91.8 ●	97.6 ●	60.9 ▲
RNA	167	160	96 ●	83.1 ▲	26.9 ▲	26.9 ▲	14.4 ▲	74.4 ▲	17.5 ▲	14.4 ▲	83.1 ●	55.6 ▲
RWP31	36	31	86 ●	93.5 ▲	74.2 ▲	71.0 ▲	61.3 ▲	87.1 ●	6.5 ▲	3.2 ▲	90.3 ●	67.7 ▲
RXW	208	207	100 ●	95.2 ●	0.0 ▲	19.3 ▲	0.0 ▲	74.4 ▲	1.9 ▲	1.9 ▲	85.5 ●	66.2 ▲

Table 1a (continued)

Data completeness for key fields England and Wales

Code	Expected number	Actual Number	% of expected	MDT Completeness (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS & Stage Completeness (%)	Treatment Recorded (%)	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at diagnosis (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)
N36	2134	2754	129 ●	98.7 ●	89.3 ●	86.7 ●	80.7 ●	92.8 ●	90.4 ●	76.7 ●	96.5 ●	84.5 ●
RE9	134	162	121 ●	100.0 ●	93.2 ●	84.0 ●	80.2 ●	85.2 ●	98.1 ●	97.5 ●	100.0 ●	99.4 ●
RLN	226	318	141 ●	97.5 ●	78.0 ●	80.5 ●	66.4 ▲	94.0 ●	95.3 ●	85.8 ●	97.2 ●	95.9 ●
RNL	170	261	154 ●	99.2 ●	85.1 ●	82.8 ●	72.8 ▲	81.2 ●	87.4 ●	59.4 ▲	96.9 ●	95.4 ●
RR7	132	220	167 ●	99.1 ●	80.5 ●	73.2 ▲	63.2 ▲	94.1 ●	99.1 ●	71.4 ▲	97.7 ●	97.3 ●
RTD	166	315	190 ●	99.4 ●	99.7 ●	94.6 ●	94.3 ●	98.1 ●	99.4 ●	73.7 ▲	99.4 ●	99.4 ●
RTF	364	372	102 ●	94.4 ▲	69.9 ▲	65.3 ▲	52.2 ▲	86.3 ●	73.1 ▲	52.2 ▲	92.2 ●	82.5 ●
RTR	270	381	141 ●	100.0 ●	99.5 ●	100.0 ●	99.5 ●	97.4 ●	97.4 ●	94.2 ●	100.0 ●	99.2 ●
RVW	300	297	99 ●	100.0 ●	96.3 ●	100.0 ●	96.3 ●	100.0 ●	89.6 ●	88.9 ●	96.0 ●	58.6 ▲
RXP	372	428	115 ●	99.5 ●	98.6 ●	93.5 ●	92.8 ●	93.7 ●	84.1 ●	75.0 ▲	92.8 ●	52.8 ▲
N37	1368	1290	94 ●	94.2 ▲	61.1 ▲	74.9 ▲	52.2 ▲	89.5 ●	69.8 ▲	66.6 ▲	85.8 ●	61.8 ▲
RC1	57	100	175 ●	100.0 ●	90.0 ●	88.0 ●	82.0 ●	95.0 ●	75.0 ▲	74.0 ▲	100.0 ●	60.0 ▲
RCX	112	136	121 ●	97.8 ●	57.4 ▲	56.6 ▲	48.5 ▲	89.7 ●	88.2 ●	88.2 ●	85.3 ●	66.2 ▲
RGM	261	10	4 ◆	100.0 ◆	100.0 ◆	100.0 ◆	100.0 ◆	100.0 ◆	100.0 ◆	90.0 ◆	100.0 ◆	50.0 ◆
RGN	108	145	134 ●	99.3 ●	82.1 ●	55.2 ▲	46.9 ▲	92.4 ●	82.1 ●	80.7 ●	94.5 ●	55.9 ▲
RGP	131	92	70 ■	80.4 ▲	71.7 ▲	73.9 ▲	59.8 ▲	90.2 ●	73.9 ▲	58.7 ▲	90.2 ●	88.0 ●
RGQ	171	155	91 ●	92.9 ▲	60.6 ▲	87.7 ●	54.2 ▲	91.6 ●	99.4 ●	98.1 ●	100.0 ●	100.0 ●
RGR	52	118	227 ●	97.5 ●	72.9 ▲	93.2 ●	69.5 ▲	82.2 ●	57.6 ▲	54.2 ▲	89.0 ●	66.9 ▲
RGT	103	174	169 ●	99.4 ●	92.0 ●	92.5 ●	85.6 ●	84.5 ●	42.0 ▲	35.6 ▲	47.1 ▲	29.9 ▲
RM1	338	301	89 ●	92.0 ▲	14.0 ▲	64.1 ▲	11.3 ▲	94.7 ●	57.1 ▲	56.5 ▲	88.0 ●	54.8 ▲
RQQ	35	58	166 ●	75.9 ▲	72.4 ▲	72.4 ▲	72.4 ▲	65.5 ▲	70.7 ▲	62.1 ▲	91.4 ●	48.3 ▲
N38	678	827	122 ●	99.8 ●	95.5 ●	96.5 ●	93.0 ●	90.3 ●	95.8 ●	85.4 ●	79.9 ●	78.1 ●
RAJ	192	221	115 ●	100.0 ●	99.5 ●	97.7 ●	97.7 ●	97.7 ●	99.5 ●	96.4 ●	91.4 ●	64.3 ▲
RDD	176	197	112 ●	99.5 ●	98.5 ●	100.0 ●	98.5 ●	91.4 ●	92.4 ●	79.7 ●	100.0 ●	98.5 ●
RDE	176	246	140 ●	100.0 ●	100.0 ●	100.0 ●	100.0 ●	96.3 ●	100.0 ●	78.9 ●	100.0 ●	100.0 ●
RQ8	134	163	122 ●	99.4 ●	79.8 ●	85.3 ●	69.3 ▲	69.9 ▲	88.3 ●	87.1 ●	9.8 ▲	39.3 ▲
N39	1923	2227	116 ●	98.7 ●	77.2 ●	82.4 ●	66.2 ▲	88.3 ●	63.5 ▲	50.2 ▲	93.1 ●	91.7 ●
RJF	62	134	216 ●	100.0 ●	96.3 ●	98.5 ●	94.8 ●	94.0 ●	100.0 ●	73.9 ▲	100.0 ●	100.0 ●
RK5	170	220	129 ●	96.8 ●	92.7 ●	90.5 ●	84.5 ●	91.4 ●	100.0 ●	97.3 ●	99.5 ●	99.5 ●
RNQ	146	191	131 ●	99.0 ●	81.7 ●	77.5 ●	68.1 ▲	49.7 ▲	84.8 ●	84.3 ●	28.8 ▲	22.0 ▲
RNS	142	150	106 ●	97.3 ●	89.3 ●	74.0 ▲	68.0 ▲	96.0 ●	66.7 ▲	27.3 ▲	98.7 ●	92.0 ●
RTG	257	266	104 ●	97.7 ●	71.8 ▲	75.6 ●	57.1 ▲	91.4 ●	97.7 ●	80.1 ●	99.6 ●	98.5 ●
RWD	349	380	109 ●	98.4 ●	57.9 ▲	77.9 ●	49.5 ▲	92.9 ●	92.6 ●	66.8 ▲	97.6 ●	97.6 ●
RWE	465	506	109 ●	99.8 ●	72.9 ▲	86.4 ●	63.0 ▲	84.4 ●	36.4 ▲	26.3 ▲	99.6 ●	98.6 ●
RX1	332	374	113 ●	99.5 ●	84.0 ●	82.1 ●	71.7 ▲	99.5 ●	0.3 ▲	0.3 ▲	99.5 ●	99.5 ●
NWW	433	490	113 ●	99.8 ●	95.3 ●	89.8 ●	86.1 ●	81.2 ●	86.1 ●	0.0 ▲	79.2 ●	43.9 ▲
RT7	111	159	143 ●	99.4 ●	94.3 ●	84.3 ●	80.5 ●	93.1 ●	69.2 ▲	0.0 ▲	88.1 ●	49.7 ▲
RT8	180	180	100 ●	100.0 ●	95.0 ●	88.9 ●	84.4 ●	60.0 ▲	97.2 ●	0.0 ▲	84.4 ●	45.6 ▲
RT9	142	151	106 ●	100.0 ●	96.7 ●	96.7 ●	94.0 ●	94.0 ●	90.7 ●	0.0 ▲	63.6 ▲	35.8 ▲
SEW	764	859	112 ●	99.7 ●	96.9 ●	97.7 ●	94.8 ●	90.6 ●	69.5 ▲	0.0 ▲	92.1 ●	33.2 ▲
RRS	110	135	123 ●	100.0 ●	99.3 ●	99.3 ●	98.5 ●	89.6 ●	100.0 ●	0.0 ▲	99.3 ●	37.0 ▲
RVE	102	138	135 ●	100.0 ●	98.6 ●	100.0 ●	98.6 ●	91.3 ●	99.3 ●	0.0 ▲	94.2 ●	22.5 ▲
RVF	276	318	115 ●	99.7 ●	94.3 ●	98.4 ●	93.1 ●	88.4 ●	34.0 ▲	0.0 ▲	90.9 ●	34.3 ▲
RWM	276	268	97 ●	99.3 ●	97.8 ●	94.8 ●	92.9 ●	93.3 ●	81.0 ●	0.0 ▲	88.8 ●	35.4 ▲

Table 1a (continued)

Data completeness for key fields England and Wales

Code	Expected number	Actual Number	% of expected	MDT Completeness (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS & Stage Completeness (%)	Treatment Recorded (%)	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at diagnosis (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)
SWW	669	623	93 ●	99.0 ●	92.6 ●	93.1 ●	86.7 ●	79.5 ●	91.0 ●	0.0 ▲	92.6 ●	41.3 ▲
RKU	34	31	91 ●	100.0 ●	100.0 ●	90.3 ●	90.3 ●	96.8 ●	83.9 ●	0.0 ▲	67.7 ▲	58.1 ▲
RR6	87	58	67 ■	100.0 ●	75.9 ●	96.6 ●	74.1 ▲	94.8 ●	98.3 ●	0.0 ▲	98.3 ●	46.6 ▲
RVA	133	143	108 ●	100.0 ●	99.3 ●	93.0 ●	93.0 ●	62.9 ▲	90.9 ●	0.0 ▲	90.2 ●	38.5 ▲
RVC	243	191	79 ●	100.0 ●	98.4 ●	93.7 ●	92.7 ●	88.0 ●	92.7 ●	0.0 ▲	97.4 ●	33.5 ▲
RVD	172	200	116 ●	97.0 ●	86.0 ●	92.0 ●	79.5 ●	76.0 ●	88.5 ●	0.0 ▲	92.0 ●	46.5 ▲
Grand Total	30374	32068	106 ●	96.1 ●	79.4 ●	81.8 ●	70.1 ▲	88.7 ●	70.8 ▲	52.8 ▲	90.2 ●	72.6 ▲

Table 1b

Data completeness for key fields Scotland

Health Board	Expected number	Actual number	% of expected	MDT completeness (%)	Performance status completeness (%)	Stage completeness (%)	Treatment recorded (%)
SCAN	1,160	1,170	101	95.9	95.6	96.2	99.8
Borders	86	76	88	100.0	100.0	100.0	100.0
D&G	141	111	79	97.3	96.4	83.8	99.1
Fife	279	319	114	91.2	95.6	93.1	100.0
Lothian	654	664	102	97.4	94.9	99.2	99.8
WoSCAN	2,482	2,183	88	99.1	87.3	82.3	100.0
Ayrshire & Arran	326	288	88	99.7	93.1	92.0	100.0
Clyde	350	318	91	95.6	58.2	64.2	100.0
Forth Valley	238	174	73	100.0	100.0	92.5	100.0
Lanarkshire	496	415	84	99.3	91.8	65.5	100.0
North Glasgow	658	632	96	100.0	90.0	88.3	100.0
South Glasgow	414	343	83	100.0	97.1	96.5	100.0
*Lorn & Islands	0	13	0	79.6	46.2	46.2	100.0
NoSCAN	1,000	881	88	95.0	94.7	94.0	99.9
Grampian	386	311	81	89.5	89.2	90.8	100.0
Orkney	7	1	14				
Shetland	7	3	43				
Highland	208	198	95	98.1	98.6	96.7	100.0
Western Isles	15	12	80				
Tayside	377	356	94	97.8	97.2	95.2	99.7
Grand Total	4,642	4,234	91	97.4	91.1	88.6	99.9

* Lorn & Islands patients are actively managed across two cancer networks - NoSCAN and WoSCAN. For the purposes of the Cancer Registries 'Expected Number' these patients are included in the NoSCAN figures only, in respect of 'Actual Number' the patients are included in both NoSCAN and WoSCAN figures depending on where they have been managed. Case ascertainment figures should be interpreted with this in mind".

Table 1c
Data completeness for key fields Northern Ireland

Code	Actual Number	MDT Completeness (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS & Stage Completeness (%)	Treatment Recorded (%)	Data Completeness Seen by Nurse Specialist (%)	*Data Completeness Nurse Specialist present at diagnosis (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)
ZT001	350	100.0 ●	86.6 ●	88.0 ●	78.0 ●	100.0 ●	100.0 ●	n/a	100.0 ●	100.0 ●
ZT002	175	100.0 ●	54.9 ▲	65.7 ▲	36.6 ▲	100.0 ●	100.0 ●	n/a	100.0 ●	100.0 ●
ZT004	152	100.0 ●	74.3 ▲	75.0 ▲	61.2 ▲	100.0 ●	100.0 ●	n/a	100.0 ●	100.0 ●
ZT005	142	100.0 ●	10.6 ▲	32.4 ▲	5.6 ▲	100.0 ●	100.0 ●	n/a	29.6 ▲	16.9 ●
Grand Total	819	100.0 ●	64.3 ▲	71.2 ▲	53.5 ▲	100.0 ●	100.0 ●	n/a	87.8 ●	85.6 ●

* Not collected on Capps system

Table 1d
Data completeness for key fields Jersey

Code	Actual Number	MDT Completeness (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS & Stage Completeness (%)	Treatment Recorded (%)	*Data Completeness Seen by Nurse Specialist (%)	*Data Completeness Nurse Specialist present at diagnosis (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)
Grand Total	32	100.0 ●	75.0 ▲	78.1 ●	53.1 ▲	90.6 ●	n/a	n/a	100.0 ●	100.0 ●

* There is no Lung Cancer Nurse Specialist in Jersey

Key

For % of Expected (Case Ascertainment)

- Case ascertainment exceeds 75%
- Case ascertainment 50-75%
- ▲ Case ascertainment less than 50%
- ◆ Tertiary Trust targets do not apply

For all other data completeness fields

- Data Completeness exceeds 75% (95% for MDT)
- ▲ Data Completeness less than 50% (95% for MDT)
- ◆ Tertiary Trust targets do not apply

Table 2a
Process, Nursing, Imaging and Clinical outcomes for England and Wales.

Code	Expected Number	Actual Number	% of expected	Discussed at MDT (%)	Histological diagnosis (%)	Patient seen by nurse Specialist (%)	Nurse specialist present at diagnosis (%)	% Having active treatment	% of patients receiving CT before bronchoscopy	% receiving surgery all cases
N01	989	1034	104.6 ●	89.7 ▲	85.9 ●	55.8 ▲	15.7 ▲	60.3 ●	90.7 ●	11.0 ●
RTX	184	219	119.0 ●	90.0 ▲	73.1 ▲	27.4 ▲	2.3 ▲	59.8 ●	88.4 ▲	14.2 ●
RXL	242	251	103.7 ●	82.1 ▲	77.7 ●	92.8 ●	56.2 ▲	62.2 ●	96.4 ●	11.6 ●
RXN	136	223	164.0 ●	93.3 ▲	86.1 ●	79.8 ▲	6.7 ▲	61.0 ●	94.3 ●	11.7 ●
RXR	427	341	79.9 ●	93.0 ▲	100.0 ●	31.1 ▲	0.3 ▲	58.9 ●	86.8 ▲	8.2 ▲
N02	2134	2125	99.6 ●	78.7 ▲	72.4 ▲	43.7 ▲	24.1 ▲	56.1 ●	75.9 ▲	11.4 ●
RBT	116	67	57.8 ■	28.4 ▲	91.0 ●	11.9 ▲	3.0 ▲	88.1 ●	63.6 ▲	9.0 ▲
RBV	165	47	28.5 ◆	12.8 ◆	97.9 ◆	27.7 ◆	4.3 ◆	78.7 ◆	100.0 ◆	0.0 ◆
RJN	89	100	112.4 ●	94.0 ▲	84.0 ●	97.0 ●	57.0 ▲	68.0 ●	91.3 ●	10.0 ▲
RM2	321	211	65.7 ◆	55.0 ◆	89.6 ◆	14.2 ◆	0.5 ◆	77.7 ◆	75.0 ◆	25.1 ◆
RM3	135	215	159.3 ●	53.5 ▲	55.8 ▲	68.8 ▲	48.8 ▲	37.7 ▲	92.5 ●	12.1 ●
RM4	89	92	103.4 ●	100.0 ●	72.8 ▲	96.7 ●	64.1 ▲	45.7 ▲	87.5 ▲	6.5 ▲
RMC	196	217	110.7 ●	91.2 ▲	59.4 ▲	77.9 ▲	56.7 ▲	54.8 ●	73.3 ▲	8.8 ▲
RMP	130	149	114.6 ●	87.2 ▲	75.2 ●	53.7 ▲	22.1 ▲	63.8 ●	60.5 ▲	13.4 ●
RRF	161	196	121.7 ●	72.4 ▲	55.1 ▲	34.2 ▲	0.5 ▲	37.8 ▲	71.1 ▲	8.7 ▲
RW3	103	120	116.5 ●	85.8 ▲	70.8 ▲	79.2 ▲	49.2 ▲	58.3 ●	86.3 ▲	11.7 ●
RW6	524	569	108.6 ●	92.6 ▲	71.5 ▲	2.3 ▲	0.2 ▲	56.9 ●	63.8 ▲	9.7 ▲
RWJ	105	142	135.2 ●	92.3 ▲	92.3 ●	84.5 ●	48.6 ▲	41.5 ▲	91.7 ●	11.3 ●
N03	1535	1827	119.0 ●	94.0 ▲	63.5 ▲	81.2 ●	53.6 ▲	56.0 ●	88.0 ▲	14.6 ●
RBL	119	321	269.7 ●	89.7 ▲	68.8 ▲	92.2 ●	85.0 ●	55.1 ●	85.4 ▲	16.8 ●
RBN	221	221	100.0 ●	95.9 ●	41.2 ▲	61.5 ▲	14.5 ▲	50.7 ▲	58.3 ▲	10.4 ▲
RBQ	212	238	112.3 ●	99.6 ●	81.5 ●	93.7 ●	89.9 ●	63.9 ●	96.9 ●	14.7 ●
REM	323	335	103.7 ●	89.6 ▲	65.7 ▲	71.0 ▲	13.7 ▲	65.7 ●	81.2 ▲	14.9 ●
REN	48	1	2.1 ◆	100.0 ◆	100.0 ◆	0.0 ◆	0.0 ◆	100.0 ◆	◆	0.0 ◆
RJR	121	209	172.7 ●	96.7 ●	60.8 ▲	72.2 ▲	46.4 ▲	55.0 ●	88.4 ▲	16.7 ●
RQ6	216	147	68.1 ■	91.8 ▲	65.3 ▲	75.5 ▲	53.1 ▲	38.1 ▲	87.7 ▲	10.2 ▲
RVY	82	157	191.5 ●	100.0 ●	66.2 ▲	94.9 ●	82.2 ●	61.1 ●	92.0 ●	17.2 ●
RWW	193	198	102.6 ●	93.4 ▲	54.0 ▲	90.9 ●	55.6 ▲	48.0 ▲	94.9 ●	13.6 ●
N06	1811	1857	102.5 ●	98.6 ●	72.2 ▲	78.3 ▲	40.9 ▲	57.6 ●	84.4 ▲	14.9 ●
RAE	240	204	85.0 ●	100.0 ●	75.0 ▲	86.8 ●	60.8 ▲	55.9 ●	96.8 ●	10.3 ▲
RCB	173	169	97.7 ●	95.3 ●	67.5 ▲	87.6 ●	68.6 ▲	59.2 ●	92.7 ●	20.7 ●
RCD	91	95	104.4 ●	94.7 ▲	83.2 ●	62.1 ▲	44.2 ▲	54.7 ●	92.2 ●	12.6 ●
RCF	118	93	78.8 ●	100.0 ●	79.6 ●	76.3 ▲	63.4 ▲	55.9 ●	61.4 ▲	18.3 ●
RR8	565	553	97.9 ●	99.1 ●	71.4 ▲	82.3 ●	0.0 ▲	63.8 ●	91.3 ●	15.6 ●
RWY	244	278	113.9 ●	98.9 ●	79.9 ●	79.9 ▲	55.8 ▲	62.9 ●	73.1 ▲	9.7 ▲
RXF	380	465	122.4 ●	98.9 ●	65.2 ▲	69.2 ▲	56.8 ▲	48.0 ▲	80.0 ▲	17.0 ●
N07	753	782	103.9 ●	98.1 ●	71.1 ▲	69.8 ▲	37.5 ▲	59.6 ●	71.3 ▲	14.6 ●
RCC	126	147	116.7 ●	99.3 ●	64.6 ▲	98.6 ●	82.3 ●	49.7 ▲	81.7 ▲	8.8 ▲
RJL	226	249	110.2 ●	94.8 ▲	66.3 ▲	82.3 ●	48.6 ▲	59.4 ●	83.8 ▲	11.2 ●
RWA	401	386	96.3 ●	99.7 ●	76.7 ●	50.8 ▲	13.2 ▲	63.5 ●	59.9 ▲	18.9 ●
N08	1246	1391	111.6 ●	99.0 ●	71.2 ▲	28.1 ▲	13.7 ▲	54.8 ●	81.4 ▲	14.6 ●
RFF	131	169	129.0 ●	95.3 ●	78.1 ●	84.0 ●	55.0 ▲	61.5 ●	78.0 ▲	9.5 ▲
RFR	144	160	111.1 ●	99.4 ●	76.3 ●	76.3 ▲	48.8 ▲	50.0 ▲	76.4 ▲	11.3 ●
RFS	174	205	117.8 ●	99.5 ●	70.2 ▲	56.6 ▲	4.9 ▲	53.7 ▲	81.3 ▲	16.1 ●
RHQ	480	453	94.4 ●	99.6 ●	69.1 ▲	1.8 ▲	1.5 ▲	54.1 ●	88.0 ▲	16.3 ●
RP5	317	404	127.4 ●	99.5 ●	69.1 ▲	0.7 ▲	0.5 ▲	55.2 ●	80.6 ▲	15.3 ●

	% receiving radiotherapy	Number of NSCLC	% of NSCLC having Surgery	Number of PS0-1 NSCLC Stage IIIB or IV	% PS0-1, Stage IIIB or IV NSCLC having chemotherapy	Number of histologically confirmed NSCLC	% of histologically confirmed NSCLC having surgery	Number of patients small cell lung cancer	% small cell receiving chemotherapy	% pre-treatment NSCLC histology NOS	Code
	32.5	833	10.9	148	63.5 ●	692	12.9	135	70.4 ●	21.5	N01
	23.7	168	11.9	13	53.8 ●	114	16.7	24	75.0 ●	27.8	RTX
	37.1	202	10.9	40	57.5 ●	146	15.1	31	74.2 ●	23.6	RXL
	29.1	170	13.5	44	68.2 ●	139	15.8	40	50.0 ▲	20.1	RXN
	37.0	293	8.9	51	66.7 ●	293	8.9	40	85.0 ●	18.6	RXR
	33.8	1820	11.5	305	42.3 ▲	1245	15.7	201	55.2 ▲	24.3	N02
	67.2	63	7.9	4	100.0 ●	57	8.8	2	100.0 ●	10.9	RBT
	63.8	42	0.0	6	50.0 ◆	41	0.0	1	100.0 ◆	0.0	RBV
	38.0	80	12.5	19	63.2 ●	64	15.6	17	64.7 ●	32.3	RJN
	33.2	158	29.1	8	75.0 ◆	140	32.1	21	90.5 ◆	16.4	RM2
	18.1	205	11.2	24	33.3 ▲	112	18.8	2	100.0 ●	9.3	RM3
	20.7	72	5.6	5	80.0 ●	47	6.4	16	68.8 ●	31.9	RM4
	31.3	182	9.3	35	54.3 ●	94	16.0	28	57.1 ▲	15.1	RMC
	36.9	118	15.3	20	75.0 ●	83	19.3	25	56.0 ▲	45.5	RMP
	28.6	175	8.6	16	0.0 ▲	87	13.8	16	6.3 ▲	22.4	RRF
	40.8	109	11.0	17	58.8 ●	74	13.5	8	50.0 ▲	21.6	RW3
	36.2	503	8.9	119	37.8 ▲	342	12.9	43	55.8 ▲	24.5	RW6
	30.3	113	12.4	32	9.4 ▲	104	13.5	22	27.3 ▲	49.0	RWJ
	32.3	1562	14.5	250	59.6 ●	902	23.5	177	62.7 ●	18.7	N03
	35.8	263	16.7	53	34.0 ▲	165	26.7	35	65.7 ●	25.5	RBL
	21.7	207	10.1	28	82.1 ●	77	24.7	11	54.5 ▲	18.3	RBN
	39.9	204	15.7	47	57.4 ●	161	19.9	26	46.2 ▲	5.0	RBQ
	40.0	290	15.9	48	70.8 ●	175	21.7	31	71.0 ●	31.4	REM
	100.0	1	0.0		◆	1	0.0		◆	0.0	REN
	28.7	168	15.5	25	56.0 ●	86	30.2	28	75.0 ●	12.8	RJR
	21.8	123	8.9	11	45.5 ▲	72	15.3	18	33.3 ▲	3.1	RQ6
	33.1	132	15.9	27	81.5 ●	79	22.8	16	81.3 ●	16.5	RVY
	27.3	174	14.4	11	54.5 ●	86	27.9	12	66.7 ●	27.3	RWW
	26.8	1548	16.1	267	58.1 ●	1039	22.4	223	75.8 ●	27.2	N06
	26.0	177	10.7	28	89.3 ●	126	12.7	20	95.0 ●	30.4	RAE
	20.1	136	22.1	29	55.2 ●	82	30.5	23	69.6 ●	42.9	RCB
	20.0	83	14.5	19	68.4 ●	67	16.4	12	83.3 ●	15.8	RCD
	21.5	78	20.5	25	68.0 ●	60	26.7	11	90.9 ●	32.2	RCF
	42.3	456	16.7	82	59.8 ●	303	24.1	64	70.3 ●	22.8	RR8
	26.6	217	10.1	28	57.1 ●	161	13.7	48	81.3 ●	40.1	RWY
	13.8	401	18.5	56	33.9 ▲	240	29.2	45	66.7 ●	19.1	RXF
	24.6	642	14.6	195	43.1 ▲	424	18.4	96	74.0 ●	32.8	N07
	21.8	124	9.7	37	54.1 ●	76	15.8	17	76.5 ●	9.5	RCC
	28.9	200	9.5	65	49.2 ●	117	15.4	31	87.1 ●	43.2	RJL
	22.8	318	19.8	93	34.4 ▲	231	20.8	48	64.6 ●	36.2	RWA
	16.7	1163	15.2	312	55.8 ●	776	20.0	160	68.1 ●	50.4	N08
	23.7	148	9.5	33	51.5 ●	111	11.7	17	58.8 ▲	35.1	RFF
	8.1	133	11.3	35	62.9 ●	95	15.8	21	81.0 ●	38.5	RFR
	7.3	159	15.7	39	56.4 ●	98	16.3	38	60.5 ▲	47.3	RFS
	22.5	382	18.6	92	66.3 ●	243	28.4	42	78.6 ●	30.0	RHQ
	15.3	341	15.2	113	46.0 ▲	229	18.3	42	61.9 ▲	93.3	RPS

Table 2a (continued)

Process, Nursing, Imaging and Clinical outcomes for England and Wales.

Code	Expected Number	Actual Number	% of expected	Discussed at MDT (%)	Histological diagnosis (%)	Patient seen by nurse Specialist (%)	Nurse specialist present at diagnosis (%)	% Having active treatment	% of patients receiving CT before bronchoscopy	% receiving surgery all cases
N11	1066	1159	108.7 ●	95.8 ●	78.9 ●	59.8 ▲	34.6 ▲	60.4 ●	86.9 ▲	17.3 ●
RBK	158	136	86.1 ●	91.9 ▲	85.3 ●	84.6 ●	64.7 ▲	75.7 ●	88.0 ▲	11.8 ●
RR1	404	460	113.9 ●	93.9 ▲	77.2 ●	29.6 ▲	18.3 ▲	55.2 ●	86.6 ▲	20.4 ●
RRK	245	261	106.5 ●	98.5 ●	82.4 ●	86.6 ●	58.2 ▲	61.7 ●	100.0 ●	16.9 ●
RXK	259	300	115.8 ●	98.7 ●	75.7 ●	71.7 ▲	25.7 ▲	60.0 ●	79.8 ▲	15.7 ●
N12	414	517	124.9 ●	96.9 ●	86.5 ●	68.9 ▲	48.9 ▲	60.9 ●	72.5 ▲	10.3 ▲
RJC	5	96	1920.0 ●	92.7 ▲	75.0 ▲	94.8 ●	65.6 ▲	38.5 ▲	70.4 ▲	4.2 ▲
RKB	249	218	87.6 ●	98.6 ●	92.7 ●	66.5 ▲	53.7 ▲	68.3 ●	77.7 ▲	14.7 ●
RLT	96	127	132.3 ●	98.4 ●	80.3 ●	80.3 ●	55.9 ▲	63.0 ●	78.5 ▲	7.1 ▲
RWV00	64	76	118.8 ●	94.7 ▲	93.4 ●	23.7 ▲	2.6 ▲	64.5 ●	50.0 ▲	10.5 ▲
N20	532	538	101.1 ●	98.1 ●	73.8 ▲	71.7 ▲	54.3 ▲	40.9 ▲	79.9 ▲	14.1 ●
RC9	109	143	131.2 ●	98.6 ●	78.3 ●	79.0 ▲	53.1 ▲	50.3 ▲	86.5 ▲	16.1 ●
RWG	217	173	79.7 ●	96.5 ●	78.0 ●	46.8 ▲	29.5 ▲	42.8 ▲	84.2 ▲	11.6 ●
RWH	206	222	107.8 ●	99.1 ●	67.6 ▲	86.5 ●	74.3 ▲	33.3 ▲	73.2 ▲	14.9 ●
N21	862	666	77.3 ●	98.3 ●	85.4 ●	74.5 ▲	65.2 ▲	57.4 ●	93.5 ●	14.0 ●
RAS	100	135	135.0 ●	99.3 ●	81.5 ●	94.8 ●	94.8 ●	19.3 ▲	98.7 ●	9.6 ▲
RC3	75	62	82.7 ●	98.4 ●	72.6 ▲	72.6 ▲	61.3 ▲	61.3 ●	73.7 ▲	6.5 ▲
RFW	70	90	128.6 ●	98.9 ●	77.8 ●	0.0 ▲	0.0 ▲	68.9 ●	100.0 ●	12.2 ●
RQM	80	60	75.0 ■	100.0 ●	93.3 ●	85.0 ●	75.0 ▲	65.0 ●	96.6 ●	20.0 ●
RT3	148	13	8.8 ◆	84.6 ◆	76.9 ◆	53.8 ◆	30.8 ◆	76.9 ◆	0.0 ◆	76.9 ◆
RV8	100	83	83.0 ●	97.6 ●	90.4 ●	83.1 ●	54.2 ▲	51.8 ▲	87.1 ▲	15.7 ●
RYJ	289	223	77.2 ●	98.2 ●	91.0 ●	87.9 ●	78.0 ▲	73.5 ●	92.8 ●	13.5 ●
N22	732	733	100.1 ●	98.4 ●	79.8 ●	88.4 ●	58.5 ▲	58.0 ●	80.8 ▲	14.9 ●
RAL	86	87	101.2 ●	98.9 ●	80.5 ●	97.7 ●	94.3 ●	47.1 ▲	87.5 ▲	14.9 ●
RAP	84	89	106.0 ●	98.9 ●	89.9 ●	96.6 ●	82.0 ●	68.5 ●	91.1 ●	24.7 ●
RKE	98	79	80.6 ●	98.7 ●	74.7 ▲	79.7 ▲	36.7 ▲	48.1 ▲	100.0 ●	13.9 ●
RQW	113	152	134.5 ●	98.7 ●	73.7 ▲	80.3 ●	46.7 ▲	59.2 ●	82.1 ▲	13.8 ●
RRV	139	115	82.7 ●	98.3 ●	83.5 ●	89.6 ●	59.1 ▲	71.3 ●	90.5 ●	12.2 ●
RVL	212	211	99.5 ●	97.6 ●	79.6 ●	89.6 ●	50.2 ▲	53.6 ▲	69.3 ▲	13.3 ●
N23	780	770	98.7 ●	92.9 ▲	75.8 ●	73.4 ▲	49.1 ▲	57.1 ●	82.1 ▲	19.9 ●
RF4	340	314	92.4 ●	92.0 ▲	84.4 ●	69.1 ▲	40.1 ▲	60.8 ●	79.3 ▲	15.6 ●
RGC	115	127	110.4 ●	95.3 ●	93.7 ●	92.9 ●	78.0 ▲	66.9 ●	84.9 ▲	26.0 ●
RNH	115	116	100.9 ●	93.1 ▲	66.4 ▲	78.4 ▲	44.0 ▲	40.5 ▲	89.2 ▲	20.7 ●
RNJ	110	102	92.7 ●	90.2 ▲	64.7 ▲	37.3 ▲	7.8 ▲	71.6 ●	66.7 ▲	31.4 ●
RQX	100	111	111.0 ●	94.6 ▲	51.4 ▲	91.0 ●	84.7 ●	39.6 ▲	86.1 ▲	13.5 ●
N24	873	803	92.0 ●	90.8 ▲	80.0 ●	69.7 ▲	58.0 ▲	58.0 ●	80.2 ▲	11.1 ●
RJ1	273	154	56.4 ■	99.4 ●	96.1 ●	90.3 ●	63.6 ▲	74.0 ●	83.0 ▲	16.9 ●
RJ2	116	93	80.2 ●	48.4 ▲	88.2 ●	1.1 ▲	1.1 ▲	60.2 ●	64.9 ▲	5.4 ▲
RJZ	114	131	114.9 ●	100.0 ●	77.9 ●	100.0 ●	99.2 ●	45.8 ▲	▲	9.9 ▲
RYQ	370	425	114.9 ●	94.1 ▲	72.9 ▲	68.0 ▲	55.8 ▲	55.5 ●	85.5 ▲	10.6 ▲
N25	785	587	74.8 ■	86.0 ▲	69.3 ▲	25.0 ▲	20.4 ▲	58.6 ●	66.4 ▲	12.6 ●
RAX	159	90	56.6 ■	86.7 ▲	73.3 ▲	75.6 ▲	63.3 ▲	47.8 ▲	81.8 ▲	5.6 ▲
RJ6	132	104	78.8 ●	96.2 ●	18.3 ▲	73.1 ▲	59.6 ▲	63.5 ●	81.8 ▲	12.5 ●
RJ7	239	157	65.7 ■	89.2 ▲	98.7 ●	1.3 ▲	0.6 ▲	80.3 ●	100.0 ●	22.9 ●
RPY	0	13	0.0 ◆	0.0 ◆	61.5 ◆	7.7 ◆	0.0 ◆	76.9 ◆	◆	15.4 ◆
RVR	245	223	91.0 ●	83.9 ▲	71.3 ▲	0.0 ▲	0.0 ▲	44.4 ▲	57.0 ▲	8.1 ▲

	% receiving radiotherapy	Number of NSCLC	% of NSCLC having Surgery	Number of PS0-1 NSCLC Stage IIIB or IV	% PS0-1, Stage IIIB or IV NSCLC having chemotherapy	Number of histologically confirmed NSCLC	% of histologically confirmed NSCLC having surgery	Number of patients small cell lung cancer	% small cell receiving chemotherapy	% pre-treatment NSCLC histology NOS	Code
	20.3	965	17.1	257	63.8 ●	726	22.0	142	70.4 ●	29.2	N11
	33.8	112	12.5	25	92.0 ●	93	15.1	20	85.0 ●	42.9	RBK
	11.1	378	18.3	92	65.2 ●	274	24.1	52	65.4 ●	26.5	RR1
	23.8	218	17.0	72	69.4 ●	173	21.4	28	60.7 ▲	16.3	RRK
	25.0	256	17.6	68	45.6 ▲	185	23.2	41	75.6 ●	38.6	RXX
	32.5	436	11.7	115	40.0 ▲	368	13.9	59	64.4 ●	27.8	N12
	12.5	78	5.1	14	64.3 ●	54	7.4	12	66.7 ●	32.1	RJC
	45.4	187	16.0	66	33.3 ▲	173	17.3	22	68.2 ●	22.9	RKB
	31.5	106	8.5	35	42.9 ▲	81	11.1	16	56.3 ▲	39.7	RLT
	22.4	65	12.3		▲	60	13.3	9	66.7 ●	20.0	RWP00
	14.9	426	15.0	98	31.6 ▲	288	20.8	72	43.1 ▲	25.2	N20
	27.3	108	16.7	29	41.4 ▲	79	17.7	19	52.6 ▲	24.0	RC9
	12.7	135	10.4	27	40.7 ▲	98	14.3	28	39.3 ▲	25.6	RWG
	8.6	183	17.5	42	19.0 ▲	111	28.8	25	40.0 ▲	25.7	RWH
	31.2	567	14.3	165	40.6 ▲	473	17.1	62	61.3 ▲	31.7	N21
	8.9	104	7.7	46	4.3 ▲	81	9.9	16	12.5 ▲	23.1	RAS
	40.3	53	5.7	10	80.0 ●	36	8.3	6	66.7 ●	11.8	RC3
	46.7	77	13.0	20	70.0 ●	57	17.5	12	75.0 ●	17.0	RFW
	40.0	53	17.0	21	42.9 ▲	50	18.0	2	50.0 ▲	70.0	RQM
	0.0	12	75.0		◆	9	100.0		◆		RT3
	13.3	73	17.8	14	50.0 ●	65	20.0	7	85.7 ●	41.9	RV8
	42.2	195	14.9	54	50.0 ●	175	16.6	19	84.2 ●	29.0	RYJ
	28.8	616	14.6	142	47.9 ▲	468	19.0	68	63.2 ●	29.3	N22
	17.2	75	16.0	8	50.0 ●	58	20.7	6	66.7 ●	16.0	RAL
	31.5	75	25.3	16	56.3 ●	66	28.8	12	83.3 ●	18.5	RAP
	15.2	68	11.8	16	56.3 ●	48	16.7	8	50.0 ▲	35.6	RKE
	40.1	120	14.2	21	38.1 ▲	80	21.3	12	50.0 ▲	35.7	RQW
	39.1	99	14.1	39	35.9 ▲	80	16.3	10	60.0 ●	12.5	RRV
	23.7	179	11.2	42	57.1 ●	136	14.7	20	65.0 ▲	46.2	RVL
	13.0	646	20.3	113	56.6 ●	463	22.0	76	60.5 ▲	25.0	N23
	11.5	248	16.1	33	63.6 ●	200	17.0	40	62.5 ●	40.8	RF4
	18.1	105	23.8	39	64.1 ●	97	24.7	13	46.2 ▲	16.8	RGC
	11.2	103	22.3	20	35.0 ▲	65	29.2	9	22.2 ▲	8.2	RNH
	13.7	86	33.7	3	100.0 ●	51	29.4	10	90.0 ●	16.7	RNJ
	12.6	104	13.5	18	44.4 ▲	50	20.0	4	100.0 ●	9.3	RQX
	28.8	684	11.5	120	63.3 ●	526	15.0	77	79.2 ●	26.4	N24
	36.4	126	19.8	20	80.0 ●	120	20.8	24	79.2 ●	26.7	RJ1
	18.3	83	4.8	11	72.7 ●	72	5.6	7	71.4 ●	27.8	RJ2
	25.2	118	11.0	28	32.1 ▲	91	14.3	7	57.1 ▲	9.9	RJZ
	29.4	357	10.4	61	70.5 ●	243	15.2	39	84.6 ●	32.5	RYQ
	28.3	506	11.3	87	62.1 ●	329	15.8	45	68.9 ●	25.2	N25
	25.6	76	6.6	14	64.3 ●	52	9.6	11	81.8 ●	22.9	RAX
	27.9	98	10.2	24	70.8 ●	16	37.5	1	100.0 ●	25.0	RJ6
	39.5	129	22.5	21	33.3 ▲	127	22.8	17	64.7 ●	26.2	RJ7
	23.1	9	11.1	1	100.0 ◆	4	25.0	1	100.0 ◆	0.0	RPY
	22.0	194	6.2	27	74.1 ●	130	8.5	15	60.0 ▲	25.9	RVR

Table 2a (continued)

Process, Nursing, Imaging and Clinical outcomes for England and Wales.

Code	Expected Number	Actual Number	% of expected	Discussed at MDT (%)	Histological diagnosis (%)	Patient seen by nurse Specialist (%)	Nurse specialist present at diagnosis (%)	% Having active treatment	% of patients receiving CT before bronchoscopy	% receiving surgery all cases
N26	920	1069	116.2 ●	92.1 ▲	75.6 ●	82.7 ●	63.7 ▲	68.9 ●	82.5 ▲	14.1 ●
RA9	156	188	120.5 ●	97.9 ●	68.6 ▲	92.6 ●	86.2 ●	61.7 ●	78.4 ▲	9.6 ▲
RBZ	85	95	111.8 ●	90.5 ▲	76.8 ●	86.3 ●	57.9 ▲	60.0 ●	74.3 ▲	21.1 ●
REF	223	286	128.3 ●	85.3 ▲	75.2 ●	87.4 ●	65.4 ▲	80.4 ●	94.8 ●	16.4 ●
RH8	200	193	96.5 ●	97.4 ●	86.0 ●	83.9 ●	68.9 ▲	74.6 ●	67.0 ▲	22.8 ●
RK9	256	307	119.9 ●	92.2 ▲	73.3 ▲	70.4 ▲	46.9 ▲	61.9 ●	90.1 ●	7.2 ▲
N27	402	467	116.2 ●	98.3 ●	73.0 ▲	90.4 ●	71.3 ▲	58.2 ●	89.4 ▲	15.4 ●
RBD	82	120	146.3 ●	98.3 ●	70.0 ▲	91.7 ●	54.2 ▲	65.8 ●	90.0 ▲	17.5 ●
RD3	150	141	94.0 ●	97.9 ●	80.9 ●	83.0 ●	51.8 ▲	57.4 ●	82.1 ▲	13.5 ●
RDZ	170	206	121.2 ●	98.5 ●	69.4 ▲	94.7 ●	94.7 ●	54.4 ●	94.1 ●	15.5 ●
N28	843	846	100.4 ●	89.7 ▲	76.4 ●	46.8 ▲	6.5 ▲	59.7 ●	86.8 ▲	14.1 ●
RA3	82	92	112.2 ●	77.2 ▲	87.0 ●	56.5 ▲	25.0 ▲	68.5 ●	81.8 ▲	12.0 ●
RA4	62	79	127.4 ●	72.2 ▲	81.0 ●	27.8 ▲	8.9 ▲	51.9 ▲	93.8 ●	20.3 ●
RA7	180	136	75.6 ●	97.8 ●	80.1 ●	57.4 ▲	0.7 ▲	61.8 ●	80.0 ▲	19.9 ●
RBA	121	180	148.8 ●	91.1 ▲	55.6 ▲	57.8 ▲	12.2 ▲	61.1 ●	92.9 ●	17.2 ●
RD1	170	145	85.3 ●	90.3 ▲	84.1 ●	79.3 ▲	0.0 ▲	59.3 ●	87.5 ▲	9.0 ▲
RVJ	228	214	93.9 ●	94.9 ▲	79.9 ●	11.7 ▲	0.9 ▲	56.5 ●	84.8 ▲	9.8 ▲
N29	437	533	122.0 ●	93.4 ▲	83.1 ●	60.8 ▲	34.7 ▲	64.9 ●	76.1 ▲	13.9 ●
RLQ	74	112	151.4 ●	95.5 ●	81.3 ●	70.5 ▲	36.6 ▲	61.6 ●	81.5 ▲	9.8 ▲
RTE	244	282	115.6 ●	94.0 ▲	83.3 ●	86.5 ●	51.1 ▲	67.7 ●	73.0 ▲	15.6 ●
RWP50	119	139	116.8 ●	90.6 ▲	84.2 ●	0.7 ▲	0.0 ▲	61.9 ●	76.5 ▲	13.7 ●
N30	1031	1205	116.9 ●	97.2 ●	80.3 ●	60.8 ▲	38.3 ▲	57.8 ●	87.9 ▲	16.1 ●
RD7	112	150	133.9 ●	92.0 ▲	87.3 ●	0.0 ▲	0.0 ▲	36.0 ▲	▲	16.7 ●
RD8	96	115	119.8 ●	94.8 ▲	94.8 ●	74.8 ▲	24.3 ▲	60.0 ●	65.1 ▲	19.1 ●
RHW	206	193	93.7 ●	99.0 ●	70.5 ▲	90.7 ●	54.4 ▲	68.4 ●	83.8 ▲	13.5 ●
RN3	113	155	137.2 ●	98.7 ●	81.9 ●	61.9 ▲	20.0 ▲	42.6 ▲	97.8 ●	14.2 ●
RTH	303	387	127.7 ●	97.9 ●	73.9 ▲	72.6 ▲	59.9 ▲	63.3 ●	97.3 ●	19.4 ●
RXQ	201	202	100.5 ●	98.0 ●	87.1 ●	45.5 ▲	31.2 ▲	62.9 ●	79.3 ▲	11.4 ●
N31	1092	1068	97.8 ●	95.2 ●	82.5 ●	62.9 ▲	29.4 ▲	67.9 ●	83.9 ▲	16.8 ●
RHM	448	262	58.5 ■	90.1 ▲	79.0 ●	33.2 ▲	24.0 ▲	82.8 ●	92.9 ●	25.2 ●
RHU	279	261	93.5 ●	96.9 ●	86.2 ●	69.7 ▲	0.4 ▲	64.0 ●	0.0 ▲	11.1 ●
RN1	94	96	102.1 ●	94.8 ▲	89.6 ●	40.6 ▲	37.5 ▲	61.5 ●	82.4 ▲	14.6 ●
RN5	39	87	223.1 ●	94.3 ▲	64.4 ▲	86.2 ●	50.6 ▲	51.7 ▲	75.0 ▲	14.9 ●
RNZ	71	101	142.3 ●	99.0 ●	84.2 ●	86.1 ●	39.6 ▲	75.2 ●	79.1 ▲	11.9 ●
RR2	53	104	196.2 ●	98.1 ●	84.6 ●	99.0 ●	92.3 ●	61.5 ●	70.7 ▲	14.4 ●
RYR	108	156	144.4 ●	97.4 ●	85.9 ●	63.5 ▲	21.8 ▲	62.2 ●	91.8 ●	19.2 ●
N32	540	613	113.5 ●	92.0 ▲	84.5 ●	66.9 ▲	29.4 ▲	59.7 ●	69.7 ▲	15.5 ●
RA2	109	75	68.8 ■	78.7 ▲	98.7 ●	34.7 ▲	4.0 ▲	60.0 ●	72.7 ▲	10.7 ▲
RDU	116	156	134.5 ●	93.6 ●	76.9 ●	74.4 ▲	9.6 ▲	51.9 ▲	75.0 ▲	16.0 ●
RTK	159	186	117.0 ●	90.9 ▲	77.4 ●	60.2 ▲	37.1 ▲	59.7 ●	50.9 ▲	21.0 ●
RTP	156	195	125.0 ●	96.9 ●	91.8 ●	80.0 ▲	47.7 ▲	66.2 ●	77.3 ▲	11.8 ●
N33	620	638	102.9 ●	99.4 ●	72.3 ▲	72.7 ▲	32.0 ▲	49.7 ▲	67.9 ▲	9.1 ▲
RPL	140	161	115.0 ●	99.4 ●	70.8 ▲	88.2 ●	61.5 ▲	44.7 ▲	58.7 ▲	9.3 ▲
RXC	229	270	117.9 ●	99.6 ●	75.9 ●	74.8 ▲	24.8 ▲	54.8 ●	70.9 ▲	9.3 ▲
RXH	251	207	82.5 ●	99.0 ●	68.6 ▲	58.0 ▲	18.4 ▲	46.9 ▲	69.4 ▲	8.7 ▲

	% receiving radiotherapy	Number of NSCLC	% of NSCLC having Surgery	Number of PS0-1 NSCLC Stage IIIB or IV	% PS0-1, Stage IIIB or IV NSCLC having chemotherapy	Number of histologically confirmed NSCLC	% of histologically confirmed NSCLC having surgery	Number of patients small cell lung cancer	% small cell receiving chemotherapy	% pre-treatment NSCLC histology NOS	Code
	45.9	878	12.4	237	55.3 ●	619	17.1	113	66.4 ●	23.5	N26
	42.6	166	9.0	57	47.4 ▲	109	13.8	12	66.7 ●	13.8	RA9
	26.3	76	18.4	12	50.0 ●	54	24.1	12	66.7 ●	57.7	RBZ
	60.1	237	13.5	33	54.5 ●	166	19.3	25	80.0 ●	9.8	REF
	47.2	154	20.8	49	57.1 ●	127	24.4	22	68.2 ●	15.2	RH8
	40.1	245	6.5	86	60.5 ●	163	9.2	42	57.1 ▲	39.5	RK9
	27.6	383	14.4	108	46.3 ▲	258	20.5	56	75.0 ●	39.1	N27
	30.0	95	15.8	20	40.0 ▲	59	23.7	18	77.8 ●	27.3	RBD
	39.7	110	11.8	32	50.0 ●	84	15.5	21	61.9 ▲	21.7	RD3
	18.0	178	15.2	56	46.4 ▲	115	22.6	17	88.2 ●	59.0	RDZ
	25.4	718	13.9	103	50.5 ●	520	17.5	67	76.1 ●	25.0	N28
	23.9	77	11.7	25	68.0 ●	65	13.8	10	90.0 ●	18.5	RA3
	13.9	68	20.6	10	20.0 ▲	53	26.4	6	33.3 ▲	29.4	RA4
	27.9	117	19.7	1	100.0 ●	91	25.3	7	85.7 ●	11.1	RA7
	22.8	153	15.0	58	44.8 ▲	74	21.6	15	80.0 ●	55.4	RBA
	24.8	120	9.2		▲	97	10.3	13	84.6 ●	37.5	RD1
	31.3	183	10.9	9	66.7 ●	140	13.6	16	68.8 ●	10.3	RVJ
	38.3	438	13.5	100	40.0 ▲	350	16.3	56	62.5 ●	53.3	N29
	37.5	88	9.1	25	44.0 ▲	67	11.9	17	70.6 ●	74.6	RLQ
	40.1	225	15.1	64	42.2 ▲	180	18.3	29	58.6 ▲	53.1	RTE
	35.3	125	13.6	11	18.2 ▲	103	15.5	10	60.0 ▲	39.6	RWP50
	21.5	1005	16.8	259	49.4 ●	771	21.4	129	62.0 ●	46.2	N30
	2.0	144	15.3	1	0.0 ▲	125	16.8		▲	100.0	RD7
	24.3	89	20.2	25	40.0 ▲	83	21.7	17	52.9 ▲	8.8	RD8
	46.6	162	12.3	43	53.5 ●	106	17.9	19	42.1 ▲	98.1	RHW
	11.0	132	14.4	35	42.9 ▲	105	18.1	17	41.2 ▲	61.3	RN3
	17.6	316	22.2	100	54.0 ●	216	31.5	45	84.4 ●	25.0	RTH
	25.7	160	11.9	54	48.1 ●	134	14.2	30	56.7 ▲	50.0	RXQ
	29.7	862	15.9	190	64.2 ●	679	19.9	111	66.7 ●	45.4	N31
	42.0	224	24.6	39	61.5 ●	171	31.6	15	80.0 ●	12.7	RHM
	26.8	190	9.5	33	48.5 ●	154	11.0	37	67.6 ●	73.2	RHU
	11.5	77	16.9	6	100.0 ●	67	19.4	15	53.3 ▲	66.1	RN1
	18.4	77	13.0	16	75.0 ●	47	21.3	5	80.0 ●	45.7	RN5
	40.6	83	13.3	32	68.8 ●	67	16.4	12	83.3 ●	47.6	RNZ
	25.0	86	14.0	28	57.1 ●	71	16.9	11	72.7 ●	36.4	RR2
	27.6	124	14.5	35	74.3 ●	102	17.6	16	43.8 ▲	31.4	RYR
	25.0	498	16.7	89	70.8 ●	404	20.0	72	34.7 ▲	19.2	N32
	28.0	63	11.1	2	100.0 ●	62	11.3	4	25.0 ▲	28.3	RA2
	17.3	125	20.0	24	45.8 ▲	90	27.8	21	42.9 ▲	17.0	RDU
	19.9	152	21.1	27	70.4 ●	110	27.3	21	38.1 ▲	3.2	RTK
	34.9	158	12.0	36	86.1 ●	142	13.4	25	28.0 ▲	27.5	RTP
	29.2	529	8.5	118	44.1 ▲	359	12.5	67	43.3 ▲	25.5	N33
	21.7	124	8.1	24	25.0 ▲	78	12.8	26	19.2 ▲	36.4	RPL
	31.5	223	8.5	56	57.1 ●	163	11.7	25	68.0 ●	15.1	RXC
	31.9	182	8.8	38	36.8 ▲	118	13.6	16	43.8 ▲	32.5	RXH

Table 2a (continued)

Process, Nursing, Imaging and Clinical outcomes for England and Wales.

Code	Expected Number	Actual Number	% of expected	Discussed at MDT (%)	Histological diagnosis (%)	Patient seen by nurse Specialist (%)	Nurse specialist present at diagnosis (%)	% Having active treatment	% of patients receiving CT before bronchoscopy	% receiving surgery all cases
N34	903	748	82.8 ●	86.6 ▲	77.3 ●	13.6 ▲	11.2 ▲	57.5 ●	94.5 ●	18.3 ●
RN7	121	103	85.1 ●	100.0 ●	86.4 ●	96.1 ●	80.6 ●	68.0 ●	94.5 ●	20.4 ●
RPA	205	81	39.5 ▲	4.9 ▲	85.2 ●	0.0 ▲	0.0 ▲	2.5 ▲	▲	0.0 ▲
RVV	374	370	98.9 ●	95.7 ●	72.4 ▲	0.0 ▲	0.0 ▲	54.1 ●	▲	17.8 ●
RWF	203	194	95.6 ●	96.4 ●	78.4 ●	1.5 ▲	0.5 ▲	81.4 ●	▲	25.8 ●
N35	1105	1022	92.5 ●	91.8 ▲	83.2 ●	51.8 ▲	31.1 ▲	60.3 ●	78.5 ▲	13.1 ●
RJD	160	167	104.4 ●	94.6 ▲	84.4 ●	95.8 ●	49.1 ▲	58.1 ●	45.9 ▲	15.6 ●
RJE	345	250	72.5 ■	92.8 ▲	77.2 ●	57.2 ▲	12.4 ▲	66.4 ●	95.5 ●	15.6 ●
RL4	189	207	109.5 ●	96.1 ●	83.6 ●	93.2 ●	87.4 ●	69.1 ●	80.0 ▲	15.0 ●
RNA	167	160	95.8 ●	78.1 ▲	83.8 ●	16.9 ▲	13.1 ▲	51.3 ▲	76.2 ▲	11.9 ●
RWP31	36	31	86.1 ●	93.5 ▲	87.1 ●	6.5 ▲	0.0 ▲	74.2 ●	83.3 ▲	25.8 ●
RXW	208	207	99.5 ●	94.2 ▲	87.9 ●	1.9 ▲	1.4 ▲	50.7 ▲	85.1 ▲	5.3 ▲
N36	2134	2754	129.1 ●	97.2 ●	72.8 ▲	81.5 ●	68.4 ▲	58.4 ●	78.3 ▲	12.2 ●
RE9	134	162	120.9 ●	100.0 ●	65.4 ▲	97.5 ●	88.3 ●	55.6 ●	85.6 ▲	6.8 ▲
RLN	226	318	140.7 ●	97.2 ●	75.8 ●	88.1 ●	82.7 ●	55.7 ●	58.6 ▲	13.5 ●
RNL	170	261	153.5 ●	98.9 ●	78.9 ●	67.4 ▲	50.2 ▲	54.8 ●	86.3 ▲	11.9 ●
RR7	132	220	166.7 ●	98.6 ●	68.6 ▲	88.2 ●	56.4 ▲	54.1 ●	95.1 ●	10.5 ▲
RTD	166	315	189.8 ●	99.0 ●	73.3 ▲	74.0 ▲	68.9 ▲	59.4 ●	81.5 ▲	12.4 ●
RTF	364	372	102.2 ●	90.1 ▲	70.2 ▲	67.2 ▲	41.9 ▲	55.1 ●	76.3 ▲	8.6 ▲
RTR	270	381	141.1 ●	96.9 ●	71.7 ▲	94.2 ●	94.0 ●	60.9 ●	91.1 ●	12.1 ●
RVW	300	297	99.0 ●	97.0 ●	75.4 ●	88.9 ●	64.0 ▲	64.6 ●	81.8 ▲	16.2 ●
RXP	372	428	115.1 ●	99.5 ●	72.7 ▲	77.3 ▲	70.3 ▲	61.4 ●	71.6 ▲	15.0 ●
N37	1368	1290	94.3 ●	91.8 ▲	81.8 ●	68.6 ▲	41.6 ▲	66.4 ●	78.3 ▲	11.3 ●
RC1	57	100	175.4 ●	97.0 ●	77.0 ●	75.0 ▲	50.0 ▲	67.0 ●	80.0 ▲	8.0 ▲
RCX	112	136	121.4 ●	90.4 ▲	87.5 ●	88.2 ●	44.9 ▲	59.6 ●	88.9 ▲	5.9 ▲
RGM	261	10	3.8 ◆	100.0 ◆	100.0 ◆	100.0 ◆	90.0 ◆	50.0 ◆	100.0 ◆	0.0 ◆
RGN	108	145	134.3 ●	93.8 ▲	75.9 ●	82.1 ●	37.9 ▲	61.4 ●	74.1 ▲	8.3 ▲
RGP	131	92	70.2 ■	79.3 ▲	80.4 ●	60.9 ▲	12.0 ▲	71.7 ●	91.7 ●	7.6 ▲
RGQ	171	155	90.6 ●	88.4 ▲	87.1 ●	98.1 ●	95.5 ●	78.7 ●	47.1 ▲	15.5 ●
RGR	52	118	226.9 ●	97.5 ●	85.6 ●	57.6 ▲	17.8 ▲	56.8 ●	92.7 ●	8.5 ▲
RGT	103	174	168.9 ●	98.9 ●	87.9 ●	42.0 ▲	31.0 ▲	59.8 ●	97.1 ●	11.5 ●
RM1	338	301	89.1 ●	91.7 ▲	76.7 ●	57.1 ▲	30.9 ▲	74.4 ●	72.1 ▲	16.9 ●
RQQ	35	58	165.7 ●	75.9 ▲	75.9 ●	67.2 ▲	60.3 ▲	53.4 ▲	100.0 ●	10.3 ▲
N38	678	827	122.0 ●	97.1 ●	77.6 ●	86.3 ●	70.9 ▲	63.8 ●	67.2 ▲	10.8 ▲
RAJ	192	221	115.1 ●	94.6 ▲	62.9 ▲	98.6 ●	95.9 ●	55.7 ●	76.8 ▲	10.0 ▲
RDD	176	197	111.9 ●	99.5 ●	77.2 ●	80.2 ●	65.0 ▲	60.9 ●	78.7 ▲	10.2 ▲
RDE	176	246	139.8 ●	95.9 ●	83.3 ●	78.9 ▲	43.5 ▲	73.6 ●	86.3 ▲	12.2 ●
RQ8	134	163	121.6 ●	99.4 ●	89.6 ●	88.3 ●	85.3 ●	63.8 ●	1.6 ▲	10.4 ▲
N39	1923	2227	115.8 ●	96.1 ●	73.7 ▲	56.2 ▲	36.0 ▲	62.5 ●	86.0 ▲	15.4 ●
RJF	62	134	216.1 ●	97.0 ●	83.6 ●	79.9 ▲	48.5 ▲	61.9 ●	76.1 ▲	16.4 ●
RK5	170	220	129.4 ●	95.0 ▲	66.4 ▲	99.1 ●	94.1 ●	50.5 ▲	74.2 ▲	11.8 ●
RNQ	146	191	130.8 ●	88.5 ▲	49.2 ▲	84.3 ●	62.8 ▲	47.6 ▲	92.3 ●	12.6 ●
RNS	142	150	105.6 ●	96.0 ●	70.7 ▲	58.0 ▲	16.7 ▲	61.3 ●	86.4 ▲	18.7 ●
RTG	257	266	103.5 ●	92.5 ▲	78.2 ●	82.3 ●	59.4 ▲	67.7 ●	93.3 ●	13.2 ●
RWD	349	380	108.9 ●	96.1 ●	77.6 ●	72.1 ▲	25.8 ▲	63.4 ●	76.9 ▲	12.9 ●
RWE	465	506	108.8 ●	99.8 ●	70.9 ▲	36.4 ▲	25.1 ▲	63.4 ●	97.6 ●	15.8 ●
RX1	332	374	112.7 ●	98.1 ●	84.5 ●	0.3 ▲	0.0 ▲	71.4 ●	93.0 ●	20.3 ●

	% receiving radiotherapy	Number of NSCLC	% of NSCLC having Surgery	Number of PS0-1 NSCLC Stage IIIB or IV	% PS0-1, Stage IIIB or IV NSCLC having chemotherapy	Number of histologically confirmed NSCLC	% of histologically confirmed NSCLC having surgery	Number of patients small cell lung cancer	% small cell receiving chemotherapy	% pre-treatment NSCLC histology NOS	Code
	25.9	606	16.8	69	39.1 ▲	443	21.9	61	52.5 ▲	21.5	N34
	26.2	81	21.0	17	76.5 ●	67	25.4	13	76.9 ●	23.5	RN7
	1.2	57	0.0		▲	46	0.0	8	0.0 ▲	30.8	RPA
	21.9	305	16.1	52	26.9 ▲	206	22.8	30	40.0 ▲	17.1	RVV
	43.8	163	22.1		▲	124	26.6	10	100.0 ●	25.7	RWF
	31.6	851	12.8	102	65.7 ●	681	15.9	120	60.0 ▲	28.0	N35
	25.7	118	10.2	23	87.0 ●	92	13.0	33	60.6 ▲	37.6	RJD
	43.6	210	16.2	12	66.7 ●	154	21.4	27	48.1 ▲	21.9	RJE
	29.0	175	15.4	57	54.4 ●	141	19.1	21	81.0 ●	32.1	RL4
	20.6	142	12.7	7	85.7 ●	117	15.4	14	57.1 ▲	12.4	RNA
	12.9	31	25.8	3	66.7 ●	27	29.6			30.8	RWP31
	35.7	175	5.7			150	6.7	25	56.0 ▲	36.0	RXW
	26.2	2253	12.6	463	62.0 ●	1536	18.0	328	68.0 ●	35.4	N36
	35.8	131	5.3	31	58.1 ●	79	8.9	14	64.3 ●	41.1	RE9
	19.2	274	14.6	34	70.6 ●	197	19.3	32	65.6 ●	52.2	RLN
	33.0	198	10.6	48	41.7 ▲	148	14.2	41	63.4 ●	33.8	RNL
	22.3	187	11.2	22	45.5 ▲	121	17.4	17	76.5 ●	41.6	RR7
	20.6	263	14.8	53	69.8 ●	182	21.4	35	65.7 ●	24.2	RTD
	14.8	306	8.8	54	66.7 ●	198	13.1	42	69.0 ●	27.1	RTF
	36.5	313	13.4	53	69.8 ●	209	20.1	49	69.4 ●	14.5	RTR
	42.4	234	15.4	62	61.3 ●	170	21.2	34	52.9 ▲	29.4	RVW
	19.2	347	15.0	106	63.2 ●	232	20.3	64	78.1 ●	58.0	RXP
	39.4	1058	10.7	199	53.8 ●	826	12.8	130	66.2 ●	35.5	N37
	51.0	80	5.0	25	44.0 ▲	58	6.9	10	50.0 ▲	36.2	RC1
	33.8	115	7.0	12	91.7 ●	98	7.1	10	90.0 ●	40.8	RCX
	30.0	7	0.0	4	50.0 ◆	7	0.0	2	50.0 ◆	14.3	RGM
	46.2	127	9.4	18	38.9 ▲	92	12.0	11	90.9 ●	32.6	RGN
	23.9	76	9.2	24	50.0 ●	58	10.3	11	81.8 ●	42.6	RGP
	50.3	127	15.7	25	68.0 ●	107	15.9	15	73.3 ●	31.7	RGQ
	18.6	100	7.0	27	70.4 ●	83	8.4	10	60.0 ▲	30.1	RGR
	29.9	140	10.7	37	40.5 ▲	119	12.6	18	55.6 ▲	18.8	RGT
	51.2	237	15.2	13	53.8 ●	169	20.7	37	59.5 ▲	46.4	RM1
	20.7	48	8.3	13	38.5 ▲	34	11.8	6	50.0 ▲	43.8	RQQ
	35.8	652	12.3	187	56.1 ●	470	16.8	102	74.5 ●	34.1	N38
	25.3	186	11.3	60	36.7 ▲	106	19.8	17	58.8 ▲	27.5	RAJ
	31.5	160	11.3	57	54.4 ●	115	15.7	20	80.0 ●	24.3	RDD
	54.1	186	14.5	55	80.0 ●	145	18.6	40	87.5 ●	46.2	RDE
	27.6	120	11.7	15	53.3 ●	104	12.5	25	60.0 ▲	34.6	RQ8
	27.2	1884	14.4	386	51.6 ●	1313	20.7	197	71.6 ●	25.4	N39
	26.1	109	14.7	29	65.5 ●	88	18.2	18	77.8 ●	13.4	RJF
	16.4	190	12.6	53	41.5 ▲	116	20.7	18	72.2 ●	29.3	RK5
	19.4	169	11.2	34	50.0 ●	79	24.1	8	75.0 ●	27.3	RNQ
	27.3	123	13.8	20	55.0 ●	79	21.5	11	54.5 ▲	28.1	RNS
	32.0	226	13.3	36	69.4 ●	171	17.5	19	73.7 ●	51.9	RTG
	34.5	315	11.4	48	43.8 ▲	232	15.5	38	65.8 ●	28.9	RWD
	28.9	424	14.9	87	58.6 ●	277	22.7	54	75.9 ●	31.9	RWE
	24.9	323	20.1	78	41.0 ▲	267	24.3	30	70.0 ●	0.0	RX1

Table 2a (continued)

Process, Nursing, Imaging and Clinical outcomes for England and Wales.

Code	Expected Number	Actual Number	% of expected	Discussed at MDT (%)	Histological diagnosis (%)	Patient seen by nurse Specialist (%)	Nurse specialist present at diagnosis (%)	% Having active treatment	% of patients receiving CT before bronchoscopy	% receiving surgery all cases	
NWW	433	490	113.2 ●	99.4 ●	69.6 ▲	79.6 ▲	0.0 ▲	56.7 ●	69.8 ▲	11.4 ●	
RT7	111	159	143.2 ●	98.1 ●	74.8 ▲	60.4 ▲	0.0 ▲	59.1 ●	73.4 ▲	11.3 ●	
RT8	180	180	100.0 ●	100.0 ●	65.6 ▲	91.7 ●	0.0 ▲	55.6 ●	80.5 ▲	12.2 ●	
RT9	142	151	106.3 ●	100.0 ●	68.9 ▲	85.4 ●	0.0 ▲	55.6 ●	48.1 ▲	10.6 ▲	
SEW	764	859	112.4 ●	97.9 ●	67.2 ▲	59.5 ▲	0.0 ▲	56.0 ●	83.9 ▲	10.7 ▲	
RRS	110	135	122.7 ●	100.0 ●	71.1 ▲	91.9 ●	0.0 ▲	63.7 ●	88.0 ▲	8.9 ▲	
RVE	102	138	135.3 ●	95.7 ●	81.2 ●	87.0 ●	0.0 ▲	67.4 ●	90.3 ●	10.1 ▲	
RVF	276	318	115.2 ●	99.4 ●	63.2 ▲	32.4 ▲	0.0 ▲	52.5 ▲	87.2 ▲	8.8 ▲	
RWM	276	268	97.1 ●	96.3 ●	62.7 ▲	61.2 ▲	0.0 ▲	50.4 ▲	75.8 ▲	14.2 ●	
SWW	669	623	93.1 ●	97.4 ●	75.9 ●	78.8 ▲	0.0 ▲	57.9 ●	75.5 ▲	9.8 ▲	
RKU	34	31	91.2 ●	100.0 ●	90.3 ●	12.9 ▲	0.0 ▲	67.7 ●	77.8 ▲	9.7 ▲	
RR6	87	58	66.7 ■	94.8 ▲	74.1 ▲	96.6 ●	0.0 ▲	69.0 ●	63.0 ▲	5.2 ▲	
RVA	133	143	107.5 ●	100.0 ●	73.4 ▲	79.0 ▲	0.0 ▲	45.5 ▲	94.5 ●	4.9 ▲	
RVC	243	191	78.6 ●	96.9 ●	74.9 ▲	91.1 ●	0.0 ▲	59.2 ●	90.6 ●	13.6 ●	
RVD	172	200	116.3 ●	96.5 ●	77.0 ●	72.0 ▲	0.0 ▲	61.0 ●	57.0 ▲	11.0 ▲	
Grand Total	30374	32068	105.6 ●	94.1 ▲	75.6 ●	64.4 ▲	38.3 ▲	59.1 ●	80.7 ▲	13.7 ●	
Range Network											
Min			74.8	78.7	63.5	13.6	0.0	40.9	66.4	9.1	
LQ			98.3	91.9	72.3	57.9	22.3	57.3	75.7	11.4	
Median			103.9	96.1	75.9	68.9	36.0	58.2	80.8	14.1	
UQ			116.0	98.1	81.1	78.6	53.9	60.4	86.4	15.1	
Max			129.1	99.4	86.5	90.4	71.3	68.9	94.5	19.9	
Range Trusts											
Min			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
LQ			92.6	92.2	70.9	53.0	2.9	54.0	74.2	9.7	
Median			110.3	96.5	77.5	75.5	43.7	60.5	82.4	12.4	
UQ			127.4	98.9	85.2	88.1	60.9	66.5	91.5	16.1	
Max			1920.0	100.0	100.0	100.0	100.0	100.0	100.0	76.9	

	% receiving radiotherapy	Number of NSCLC	% of NSCLC having Surgery	Number of PS0-1 NSCLC Stage IIIB or IV	% PS0-1, Stage IIIB or IV NSCLC having chemotherapy	Number of histologically confirmed NSCLC	% of histologically confirmed NSCLC having surgery	Number of patients small cell lung cancer	% small cell receiving chemotherapy	% pre-treatment NSCLC histology NOS	Code
	33.3	417	12.7	133	56.4 ●	269	19.3	55	60.0 ▲	29.0	NWW
	33.3	135	11.9	46	52.2 ●	95	16.8	18	72.2 ●	19.8	RT7
	32.2	155	14.2	55	49.1 ●	93	22.6	17	58.8 ▲	40.4	RT8
	34.4	127	11.8	32	75.0 ●	81	18.5	20	50.0 ▲	26.7	RT9
	38.5	706	11.0	224	42.4 ▲	428	17.1	115	72.2 ●	42.2	SEW
	49.6	114	9.6	37	35.1 ▲	75	13.3	18	77.8 ●	21.3	RRS
	50.0	106	11.3	36	41.7 ▲	80	15.0	27	70.4 ●	76.3	RVE
	34.0	264	8.0	65	53.8 ●	147	12.9	39	64.1 ●	40.7	RVF
	32.5	222	15.3	86	37.2 ▲	126	25.4	31	80.6 ●	34.7	RWM
	33.1	524	10.1	167	52.7 ●	376	13.8	71	71.8 ●	25.7	SWW
	19.4	25	8.0	8	100.0 ●	22	9.1	4	100.0 ●	50.0	RKU
	41.4	52	5.8	19	63.2 ●	37	8.1	5	100.0 ●	18.9	RR6
	23.8	118	5.1	36	41.7 ▲	80	7.5	19	68.4 ●	7.6	RVA
	30.4	165	13.9	56	51.8 ●	117	19.7	16	68.8 ●	25.9	RVC
	42.0	164	11.6	48	50.0 ●	120	15.0	27	66.7 ●	35.3	RVD
	28.9	26676	13.7	5708	53.3 ●	19021	18.3	3443	65.7 ●	30.5	
	13.0	383.0	8.5	69.0	31.6	258.0	12.5	45.0	34.7	18.7	
	25.7	526.5	11.6	110.5	43.6	390.0	15.8	67.0	60.9	25.1	
	28.8	684.0	13.9	165.0	53.8	473.0	18.0	96.0	66.4	27.8	
	32.8	985.0	15.1	243.5	60.8	748.5	20.6	132.5	71.7	34.7	
	45.9	2253.0	20.3	463.0	70.8	1536.0	23.5	328.0	79.2	53.3	
	0.0	1.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	
	20.1	86.5	9.5	17.0	42.9	67.0	13.3	11.0	56.2	17.1	
	27.4	132.5	12.7	29.0	54.5	96.0	16.9	17.5	66.7	27.5	
	36.6	193.0	15.9	48.0	68.4	141.8	21.7	28.0	80.0	38.8	
	100.0	503.0	100.0	119.0	100.0	342.0	100.0	64.0	100.0	100.0	

Table 2b
Process and clinical outcomes for Scotland

Health Board	Actual Number	% of expected	Discussed at MDT (%)	Histological diagnosis (HCR) (%)	% having active treatment	% of patients receiving CT before bronchoscopy	% receiving surgery all cases	% receiving radiotherapy	Number of NSCLC	% of NSCLC having Surgery	Number of patients small cell lung cancer	% small cell receiving chemotherapy
SCAN	1,170	101	95.9	71.4	60.4	93.5	11.7	42.3	661	19.5	165	68.5
Borders	76	88	100.0	67.1	73.7	94.1	15.8	50.0	38	28.9	12	66.7
D&G	111	79	97.3	79.3	70.3	88.5	7.2	58.6	67	11.9	21	76.2
Fife	319	114	91.2	70.8	49.8	99.3	10.0	36.4	186	16.7	39	66.7
Lothian	664	102	97.4	70.8	62.3	90.7	12.8	41.6	370	21.4	93	67.7
WoSCAN	2183	88	95.2	80.6	62.9	83.9	11.9	37.0	1405	17.5	349	68.5
Ayrshire & Arran	288	88	99.3	85.1	58.7	83.5	11.5	30.2	190	16.3	55	65.5
Clyde	318	91	91.8	81.4	66.4	75.6	11.9	44.0	211	17.1	46	56.5
Forth Valley	174	73	100.0	69.5	58.0	94.3	11.5	31.6	90	20.0	30	60.0
Lanarkshire	415	84	98.3	88.4	62.4	83.4	15.2	29.4	305	20.0	61	75.4
North Glasgow	632	96	93.0	78.6	65.7	82.1	10.9	40.2	386	16.8	110	71.8
South Glasgow	343	83	94.2	75.2	61.2	91.4	10.5	42.0	212	16.5	45	75.6
Lorn & Islands	13	0	61.5	100.0	69.2	81.8	0.0	46.2	11	0.0	2	0.0
NoSCAN	881	88	95.0	78.7	74.2	87.6	9.3	48.2	566	12.2	116	73.3
Grampian	311	81	89.5	79.0	83.5	81.3	9.8	58.7	201	12.4	43	67.4
Orkney	1	14										
Shetland	3	43										
Highland	198	95	98.1	82.4	66.7	93.4	7.6	34.3	143	9.8	28	92.9
Western Isles	12	80										
Tayside	356	94	97.8	76.1	70.2	89.5	9.8	47.2	222	13.5	45	66.7
Grand Total	4234	91	95.3	77.7	64.6	86.4	11.3	40.8	2632	16.9	630	69.4

Lorn & Islands patients are actively managed across two cancer networks – NoSCAN and WoSCAN. This number shows the treatment method of only the patients who were managed by WoSCAN.

Table 2c
Process and clinical outcomes for Northern Ireland

Code	Actual Number	Discussed at MDT (%)	Histological diagnosis (%)	Patient seen by nurse Specialist (%)	Nurse Specialist present at diagnosis (%)**	% Having active treatment	% of patients receiving CT before bronchoscopy	% receiving surgery all cases
ZT001	350	98.0 ●	71.7 ▲	60.6 ▲	n/a	68.6 ●	92.4 ●	13.7 ●
ZT002	175	93.7 ▲	82.3 ●	71.4 ▲	n/a	61.1 ●	80.5 ▲	16.0 ●
ZT004	152	92.1 ▲	65.8 ▲	61.2 ▲	n/a	55.9 ●	85.6 ▲	9.9 ▲
ZT005*	142	71.1 ▲	59.9 ▲	82.4 ●	n/a	69.0 ●	79.2 ▲	13.4 ●
Grand Total	819	91.3 ▲	70.8 ▲	66.8 ▲	n/a	64.7 ●	87.2 ▲	13.4 ●

Table 2c (continued)
Process and clinical outcomes for Northern Ireland

Code	% receiving radiotherapy	Number of NSCLC	% of NSCLC having Surgery	Number of PS0-1 NSCLC Stage IIIB or IV	% PS0-1, Stage IIIB or IV NSCLC having chemotherapy	Number of histologically confirmed NSCLC	% of histologically confirmed NSCLC having surgery	Number of patients small cell lung cancer	% small cell receiving chemotherapy	% pre-treatment NSCLC histology NOS
ZT001	30.0	280	15.7	54	44.4 ▲	186	18.3	55	63.6 ●	30.1
ZT002	18.9	143	17.5	13	53.8 ●	115	21.7	26	69.2 ●	4.3
ZT004	24.3	132	9.8	33	36.4 ▲	82	14.6	14	71.4 ●	26.6
ZT005*	32.4	118	14.4	1	100.0 ●	61	19.7	22	77.3 ●	67.2
Grand Total	27.0	673	14.7	101	43.6 ▲	444	18.7	117	68.4 ●	27.8

* Variations in the data returns from this Trust reflect the transition from an earlier database to the comprehensive Capps database now used throughout Northern Ireland.

** Not collected on Capps system

Table 2d

Process and clinical outcomes for Jersey

Code	Actual Number	Discussed at MDT (%)	Histological diagnosis (%)	*Patient seen by nurse Specialist (%)	*Nurse Specialist present at diagnosis (%)	% Having active treatment	**% of patients receiving CT before bronchoscopy	% receiving surgery all cases
Grand Total	32	87.5 ▲	90.6 ●	n/a	n/a	71.9 ●	57.1 ▲	9.4 ▲

Table 2d (continued)

Process and clinical outcomes for Jersey

Code	% receiving radio therapy	Number of NSCLC	% of NSCLC having Surgery	Number of PS0-1 NSCLC Stage IIIB or IV	% PS0-1, Stage IIIB or IV NSCLC having chemotherapy	Number of histologically confirmed NSCLC	% of histologically confirmed NSCLC having surgery	Number of patients small cell lung cancer	% small cell receiving chemotherapy	% pre-treatment NSCLC histology NOS
Grand Total	53.1	22	13.6	4	75.0 ●	19	15.8	10	90.0 ●	33.3

* There is no Lung Cancer Nurse Specialist in Jersey.

** Jersey appreciate the NICE guidelines about CT being performed before bronchoscopy : Locally, this is dependent on access to CT and the lead clinician often can perform a bronchoscopy within a few days of seeing the patient. CT are requested but the wait is often longer than for bronchoscopy.

Key

For % of Expected (Case Ascertainment)

- Case ascertainment exceeds 75%
- Case ascertainment 50-75%
- ▲ Case ascertainment less than 50%
- ◆ Tertiary Trust targets do not apply

For all other targets

- Achieved LAP target set in 2009 report
- ▲ Did not achieve LAP target set in 2009
- ◆ Tertiary Trust. Targets do not apply as most patients are not 'first seen' at tertiary trusts. These trusts often fully participate in the audit and their performance must not be judged from data shown.

Standards

Discussed at MDT (%) >>> 95%
 Histological diagnosis (%) >>> 75%
 Patient seen by nurse Specialist (%) >>> 80%
 Nurse specialist present at diagnosis (%) >>> 80%
 % of patients receiving CT before bronchoscopy >>> 90%

BENCHMARKS (taken from 2009 local action plan)

% Having active treatment = 54%
 % receiving surgery all cases = 11%
 % PS0-1, Stage IIIB or IV NSCLC having chemotherapy = 48%
 % small cell receiving chemotherapy = 62%

Appendices

Appendix 1: Trust identification for England and Wales

N01	Lancashire and South Cumbria
RTX	University Hospitals of Morecombe Bay NHS Foundation Trust
RXL	Blackpool, Fylde and Wyre Hospitals NHS Foundation Trust
RXN	Lancashire Teaching Hospitals NHS Foundation Trust
RXR	East Lancashire Hospitals NHS Trust
N02	Greater Manchester and Cheshire
RBT	Mid Cheshire Hospitals NHS Foundation Trust
RBV	The Christie Hospital NHS Foundation Trust
RJN	East Cheshire NHS Trust
RM2	University Hospital of South Manchester NHS Foundation Trust
RM3	Salford Royal Hospitals NHS Foundation Trust
RM4	Trafford Healthcare NHS Trust
RMC	Royal Bolton Hospitals NHS Foundation Trust
RMP	Tameside Hospitals NHS Foundation Trust
RRF	Wrightington, Wigan and Leigh NHS Foundation Trust
RW3	Central Manchester University Hospital NHS Foundation Trust
RW6	Pennine Acute Hospitals NHS Trust
RWJ	Stockport NHS Foundation Trust
N03	Merseyside and Cheshire
RBL	Wirral University Teaching Hospital Foundation NHS
RBN	St Helens and Knowsley Hospitals NHS Trust
RBQ	Liverpool Heart and Chest NHS Foundation Trust
REM	Aintree University Hospitals NHS Foundation Trust
REN	Clatterbridge Centre for Oncology NHS FoundationTrust
RJR	Countess of Chester Hospital NHS Foundation Trust
RQ6	Royal Liverpool and Broadgreen University Hospitals NHS Trust
RVY	Southport and Ormskirk Hospital NHS Trust
RWW	Warrington and Halton Hospitals NHS Foundation Trust
N06	Yorkshire Cancer Network
RAE	Bradford Teaching Hospitals NHS Foundation Trust
RCB	York Hospitals NHS Foundation Trust
RCD	Harrogate and District NHS Foundation Trust
RCF	Airedale NHS Foundation Trust
RR8	Leeds Teaching Hospitals NHS Trust
RWY	Calderdale and Huddersfield NHS Foundation Trust
RXF	Mid Yorkshire Hospitals NHS Trust
N07	Humber and Yorkshire Coast Cancer Network
RCC	Scarborough and North East Yorkshire Healthcare NHS Trust
RJL	Northern Lincolnshire and Goole Hospitals NHS Foundation Trust
RWA	Hull and East Yorkshire Hospitals NHS Trust
N08	North Trent
RFF	Barnsley Hospital NHS Foundation Trust
RFR	The Rotherham NHS Foundation Trust
RFS	Chesterfield Royal Hospital NHS Foundation Trust
RHQ	Sheffield Teaching Hospitals NHS Foundation Trust
RP5	Doncaster and Bassetlaw Hospitals NHS Foundation Trust
N11	Pan Birmingham
RBK	Walsall Hospitals NHS Trust
RR1	Heart of England NHS Foundation Trust
RRJ	The Royal Orthopaedic Hospital NHS Foundation Trust
RRK	University Hospital Birmingham NHS Foundation Trust
RXK	Sandwell and West Birmingham Hospitals NHS Foundation Trust
N12	Arden
RJC	South Warwickshire General Hospitals NHS Foundation Trust
RKB	University Hospitals Coventry and Warwickshire NHS Trust
RLT	George Elliot Hospital NHS Trust
RWP01	Worcestershire Acute Hospitals NHS Trust

N20	Mount Vernon Cancer Network
RC9	Luton and Dunstable Hospital NHS Foundation Trust
RWG	West Hertfordshire Hospitals NHS Trust
RWH	East and North Hertfordshire NHS Trust
N21	West London Cancer Network
RAS	The Hillingdon Hospital NHS Trust
RC3	Ealing Hospital NHS Trust
RFW	West Middlesex University Hospital NHS Trust
RQM	Chelsea and Westminster Hospitals NHS Foundation Trust
RT3	Royal Brompton and Harefield NHS Foundation Trust
RV8	North West London Hospitals NHS Trust
RYJ	Imperial College Healthcare NHS Trust
N22	North London
RAL	Royal Free Hampstead NHS Trust
RAP	North Middlesex University Hospitals NHS Trust
RKE	The Whittington Hospital NHS Trust
RQW	The Princess Alexandra Hospital NHS Trust
RRV	University College London Hospitals NHS Foundation Trust
RVL	Barnet and Chase Farm Hospitals NHS Trust
N23	North East London Cancer Network
RF4	Barking, Havering and Redbridge University Hospitals NHS Trust
RGC	Whipps Cross University Hospital NHS Trust
RNH	Newham University Hospital NHS Trust
RNJ	Barts and the London NHS Trust
RQX	Homerton University Hospital NHS Foundation Trust
N24	South East London
RJ1	Guy's and St Thomas' NHS Foundation Trust
RJ2	Lewisham Healthcare NHS Trust
RJZ	King's College Hospital NHS Foundation Trust
RYQ	South London Healthcare NHS Trust
N25	South West London
5LG	Queen Mary's Hospital PCT NHS Trust
RAX	Kingston Hospital NHS Trust
RJ6	Croyden Health Services NHS Trust
RJ7	St George's Healthcare NHS Trust
RPY	The Royal Marsden NHS Foundation Trust
RVR	Epsom and St Helier University Hospitals NHS Trust
N26	Peninsula
RA9	South Devon Health Care NHS Foundation Trust
RBZ	Northern Devon Health Care NHS Trust
REF	Royal Cornwall Hospitals NHS Trust
RH8	Royal Devon and Exeter NHS Foundation Trust
RK9	Plymouth Hospitals NHS Trust
N27	Dorset Cancer Network
RBD	Dorset County Hospital NHS Foundation Trust
RD3	Poole Hospital NHS Foundation Trust
RDZ	The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
N28	Avon Somerset and Wiltshire
RA3	Weston Area Health NHS Trust
RA4	Yeovil District Hospital NHS Foundation Trust
RA7	University Hospitals Bristol Foundation NHS Trust
RBA	Taunton and Somerset NHS Foundation Trust
RD1	Royal United Hospital Bath NHS Trust
RVJ	North Bristol NHS Trust

N29	3 Counties Cancer Network
RLQ	Hereford Hospitals NHS Trust
RTE	Gloucestershire Hospitals NHS Foundation Trust
RWP50	Worcestershire Acute Hospitals NHS Trust

N30	Thames Valley
RD7	Heatherwood and Wexham Park Hospitals NHS Foundation Trust
RD8	Milton Keynes Hospital NHS Foundation Trust
RHW	Royal Berkshire NHS Foundation Trust
RN3	Great Western Hospitals NHS Foundation Trust
RP1	Northamptonshire Healthcare NHS Foundation Trust
RTH	Oxford Radcliffe Hospitals NHS Trust
RXQ	Buckinghamshire Hospitals NHS Trust

N31	Central South Coast
RHM	Southampton University Hospitals NHS Trust
RHU	Portsmouth Hospitals NHS Trust
RN1	Winchester and Eastleigh Healthcare NHS Trust
RN5	Basingstoke and North Hampshire NHS Foundation Trust
RNZ	Salisbury NHS Foundation Trust
RYR	Western Sussex Hospital NHS Trust
5QT	Isle of Wight NHS PCT

N32	Surrey, West Sussex and Hampshire
RA2	Royal Surrey County Hospital NHS Foundation Trust
RDU	Frimley Park Hospital NHS Foundation
RTK	Ashford and St Peter's Hospitals NHS Trust
RTP	Surrey and Sussex Healthcare NHS Trust

N33	Sussex
RPL	Worthing and Southlands Hospital NHS Trust
RXC	East Sussex Hospitals NHS Trust
RXH	Brighton and Sussex University Hospitals NHS Trust

N34	Kent and Medway
RN7	Dartford and Gravesham NHS Trust
RPA	Medway NHS Foundation Trust
RVV	East Kent Hospitals University NHS Foundation Trust
RWF	Maidstone and Tunbridge Wells NHS Trust

N35	Greater Midlands
RJD	Mid Staffordshire NHS Foundation Trust
RJE	University Hospital of North Staffordshire NHS Trust
RL4	The Royal Wolverhampton Hospitals NHS Trust
RNA	The Dudley Group of Hospitals NHS Foundation Trust
RWP01	Worcestershire Acute Hospitals NHS Trust
RXW	Shrewsbury and Telford Hospital NHS Trust

N36	North of England Cancer Network
RE9	South Tyneside NHS Foundation Trust
RLN	City Hospitals Sunderland NHS Foundation Trust
RNL	North Cumbria University Hospitals NHS Trust
RR7	Gateshead Health NHS Foundation Trust
RTD	The Newcastle Upon Tyne Hospitals NHS Foundation Trust
RTF	Northumbria Health Care NHS Foundation Trust
RTR	South Tees Hospitals NHS Foundation Trust
RVW	North Tees and Hartlepool NHS Foundation Trust
RXP	County Durham and Darlington NHS Foundation Trust

N37	Anglia Cancer Network
RC1	Bedford Hospital NHS Trust
RCX	The Queen Elizabeth Hospital King's Lynn NHS Trust
RGM	Papworth Hospital NHS Foundation Trust
RGN	Peterborough and Stamford Hospitals NHS Foundation Trust
RGP	James Paget University Hospitals NHS Foundation Trust
RGQ	Ipswich Hospital NHS Trust
RGR	West Suffolk Hospitals NHS Trust
RGT	Cambridge University Hospitals NHS Foundation Trust
RM1	Norfolk and Norwich University Hospital NHS Foundation Trust
RQQ	Hinchingbrooke Health care NHS Trust

N38	Essex Cancer Network
RAJ	Southend University Hospital NHS Foundation Trust
RDD	Basildon and Thurrock University Hospitals NHS Foundation Trust
RDE	Colchester Hospital University NHS Foundation Trust
RQ8	Mid Essex Hospital Services NHS Trust

N39	East Midland Cancer Network
RK5	Sherwood Forest Hospitals NHS Foundation Trust
RWD	United Lincolnshire Hospitals NHS Trust
RX1	Nottingham University Hospitals NHS Trust
RJF	Burton Hospitals NHS Foundation Trust
RTG	Derby Hospitals NHS Foundation Trust
RNQ	Kettering General Hospital NHS Foundation Trust
RNS	Northampton General Hospital NHS Trust
RWE	University Hospitals of Leicester NHS Trust

SEW	South East Wales Regional Cancer Network
RWM	Cardiff and Vale NHS Trust
RR5	North Glamorgan NHS Trust
RVE	Pontypridd and Rhondda NHS Trust
RVF	Gwent Healthcare NHS Trust

SWW	South West Wales Regional Cancer Network
RVA	Carmarthenshire NHS Trust
RKU	Ceredigion and Mid Wales NHS Trust
RR6	Pembrokeshire and Derwyn NHS Trust
RVC	Swansea NHS Trust
RVD	Bro Morgannwg NHS Trust

NWW	North Wales Regional Cancer Network
RT7	North West Wales NHS Trust
RT8	Conway and Denbighshire NHS Trust
RT9	North East Wales NHS Trust

Northern Ireland	Northern Ireland Cancer Network
ZT001	Belfast Health & Social Care Trust
ZT002	Northern Health & Social Care Trust
ZT004	South Eastern Health & Social Care Trust
ZT005	Western Health & Social Care Trust

Appendix 2: Local Action Plan

Recommendation	Achieved Y/N/P/NK	Planned Action	Suggested Actions	Suggested Responsibility	Date plan actioned	Date issue resolves
Data Completeness and Quality						
The trust participates in this national audit			Contact local Cancer Network for audit Advice. Contact CASU Lung Cancer Audit Project Manager (roz.stanley@ic.nhs.uk) Visit www.ic.nhs.uk/services/nationalclinical-audit-support-programme-ncasp for information. Obtain read and disseminate the Lung Cancer Audit Annual Report	Cancer Manager / Governance Lead		
Data on all patients diagnosed with either lung cancer or mesothelioma are submitted to the audit			Use MDT meetings to capture all cases discussed, Try to record cases in real time or near real time. Liaise with pathology departments to correlate cases. Work with IT department to set up CSV file upload facility if information is collected on a third party system or identify resources to input data directly	MDT Chair		
All relevant data fields are completed for each patient			Use proforma for data collection at MDT. Identify key person to QA data prior to submission. Data imputers understand clinical implications of data. Map and allocate responsibility along patient pathway. Agree protocols and submission routes for patients that are treated across different organisations	Data Co-ordinator / Cancer Manager / Network Manager		
Key data fields including stage and performance status should be completed in at least 85 per cent and in at least 95 per cent with respect to the MDT field			Refer to the documentation on the National Lung Cancer Audit Website and ensure that key fields are completed for all relevant cases. Assist MDT co-ordinator by chair ensuring that stage, performance status and other key fields are discussed and recorded for each patient	MDT Chair, Data Co-ordinator / Cancer Manager/ Network Manager		
FEV1 absolute and % predicted for stage I and II NSCLC patients with PS 0 or 1 should be recorded in at least 85%						
Process of Care						
Over 95 per cent of patients submitted to the audit are discussed at an MDT			Liaise with cancer waiting times team to identify lung cancer referrals. Liaise with radiology department to identify all imaging suspicious of lung cancer or mesothelioma. Liaise with pathology department to identify cases	MDT chair, Lung cancer clinical lead		
The Histological Confirmation Rate should be at least 75 per cent To be reviewed in light of case mix adjusted odds ratio			This result should be interpreted in conjunction with the case-mix adjusted odds ratio, which might better reflect whether the organisation is an outlier. Ensure all histological diagnoses are submitted to the audit. Liaise with pathology department to identify cases. Review clinical diagnoses and diagnostics protocols if HCR is below optimum	MDT chair, Lung cancer clinical lead		
The proportion of patients receiving CT prior to bronchoscopy should exceed 90 per cent			Ensure that all CT / bronchoscopy data is submitted to the audit. Review diagnostics protocols if rate is below optimum	MDT chair, Lung cancer clinical lead, Radiologists		

Recommendation	Achieved Y/N/P/NK	Planned Action	Suggested Actions	Suggested Responsibility	Date plan actioned	Date issue resolves
Process of Care (continued)						
Over 80 per cent of patients are seen by a lung cancer specialist nurse			Review the specialist nurse service, ensuring there are sufficient funded posts to provide a high quality service and that clear referral pathways exist	MDT chair, Lung cancer clinical lead, specialist nurse; local managers		
Over 80 per cent of patients have a lung cancer specialist nurse present at the time of diagnosis			Review the specialist nurse service, allocate extra nursing support alongside lung cancer clinics	MDT chair, Lung cancer clinical lead, specialist nurse, Local managers		
Co-morbidity that prevents a patient receiving treatment of choice should be recorded for all relevant cases			Ensure that all relevant co-morbidity data is discussed at MDT, and ensure that cases where co-morbidity prevents treatment of choice are submitted to the audit. It is important that the collected data adheres to the definitions in the LUCADA data manual.	MDT chair, Lung cancer clinical lead, specialist nurse		
PET Scan dates should be recorded for all relevant cases			Ensure that all PET data is captured at MDT submitted to the audit	MDT chair, Lung cancer clinical lead, specialist nurse		
Clinical Outcomes						
Surgical resection rates below 14% per cent for all patients excluding small cell lung cancer or mesothelioma must be reviewed. To be reviewed in light of case mix adjusted odds ratio			This result should be interpreted in conjunction with the case-mix adjusted odds ratio, which might better reflect whether the organisation is an outlier. Ensure that all surgical resections are submitted to the audit. If data is complete then review treatment policies for early stage lung cancer in patients with good performance status. Ensure that thoracic surgeon attends MDT meetings	MDT chair, Lung cancer clinical lead, thoracic surgeons		
Surgical resection rates for patients for all patients excluding small cell lung cancer or mesothelioma with stage I or II disease below 52 per cent must be reviewed			This result should be interpreted in conjunction with the case-mix adjusted odds ratio, which might better reflect whether the organisation is an outlier. Ensure that all surgical resections are submitted to the audit. If data is complete then review treatment policies for early stage lung cancer in patients with good performance status. Ensure that thoracic surgeon attends MDT meetings	MDT chair, Lung cancer clinical lead, thoracic surgeons		
Active anti-cancer treatment rates below 60 per cent should be reviewed To be reviewed in light of case mix adjusted odds ratio			This result should be interpreted in conjunction with the case-mix adjusted odds ratio, which might better reflect whether the organisation is an outlier. Ensure that all treatments are submitted to the audit. Review treatment policies for lung cancer patients	MDT chair, Lung cancer clinical lead. MDT members		
Chemotherapy rates for small cell lung cancer below 65 per cent should be reviewed To be reviewed in light of case mix adjusted odds ratio			This result should be interpreted in conjunction with the case-mix adjusted odds ratio, which might better reflect whether the organisation is an outlier. Ensure that all treatments are submitted to the audit. Review treatment policies for small cell lung cancer patients	MDT chair, Lung cancer clinical lead. MDT members		
Chemotherapy rates for patients of PS 0-1 with advanced stage NSCLC IIIB/IV below 55 per cent should be reviewed To be reviewed in light of case mix adjusted odds ratio			This result should be interpreted in conjunction with the case-mix adjusted odds ratio, which might better reflect whether the organisation is an outlier. Ensure that all treatments are submitted to the audit. Review treatment policies for non small cell lung cancer patients with advanced stage.	MDT chair, Lung cancer clinical lead. MDT members		
Low median survival, as demonstrated by a case-mix adjusted hazard ratio significantly below the baseline, should be investigated.			Ensure that all relevant data has been submitted to the audit. Identify areas where audit standards have not been met or where CMA demonstrates the trust to be an outlier and review	MDT chair, Lung cancer clinical lead. MDT members		

Appendix 3: Glossary

Adenocarcinoma

A cancer of glandular tissue e.g. the mucus-secreting cells that line the airways in lung cancer this is classified as a type of non-small cell lung cancer. It is less strongly associated with smoking than some other types of lung cancer

Anti-cancer

Treatment treatment to cure or control cancer progression

Asbestos

A fibrous silicate material

benchmarking

A method of comparing processes and outcomes against standards

Cancer Network

A system within the NHS to organise the integrated care of cancer patients across a region

Case ascertainment

Number of cases recorded as a proportion of those expected

Casemix

A means of classifying patients for comparing quality of care

Casemix-adjusted

Performance and outcome data corrected for various factors including the age, social deprivation, extent of disease and fitness of the populations under study

CASU

Clinical Audit Support Unit

Chemotherapy

Drugs used in the treatment of cancer

Cytological

From the study of cells

Deprivation

Absence of expected level of social provision

Diagnosis

Confirming the presence of the disease

Histological

From the study of tissues

Interquartile range

The range of a particular variable excluding the highest quarter and lowest quarter of the values recorded

MDT

Multi-disciplinary team

Mesothelioma

Cancer of the lining of the lung caused by asbestos

NCASP

National Clinical Audit Support Programme

Network

See 'Cancer Network'

NLCA

National Lung Cancer Audit

Non-small cell carcinoma

A group of lung cancer including squamous carcinoma and adenocarcinoma

NSCLC

Non-small cell lung cancer

Performance Status

A systematic method of recording the ability of an individual to undertake the tasks of normal daily life compared with that of a normal person

Radiotherapy

Cancer treatment using radiation

SCLC

Small cell lung cancer (small cell carcinoma)

Secondary care

Care provided by a hospital

Small cell carcinoma

Type of neuroendocrine lung cancer strongly associated with smoking

Squamous cell carcinoma

Cancer of cells that cover or line organs of the body e.g. line the tubes of the lung. In lung cancer this is classified as a type of non-small cell lung cancer, it is strongly associated with smoking

Staging / stage

The anatomical extent of a cancer

Surgical resection

An operation to remove abnormal tissues or organs

Thoracic surgeon

Specialist surgeon who operates on the chest and lungs

The NHS Information Centre for health and social care (The NHS IC) is working to make information more relevant and accessible to the public, regulators, health and social care professionals and policy makers, leading to improvements in knowledge and efficiency. The NHS IC is a special NHS health authority that collects analyses and distributes data to reduce the burden on frontline staff, releasing more time for direct care.

Document reference: IC03020211

Copyright © 2011, The NHS Information Centre, National Lung Cancer audit. All rights reserved.

This work remains the sole and exclusive property of The NHS Information Centre and may only be reproduced where there is explicit reference to the ownership of The NHS Information Centre.

This work may be re-used by NHS and government organisations without permission. Commercial re-use of this work must be granted by The NHS Information Centre.

Need to know more?

T. 0845 300 6016
E. enquiries@ic.nhs.uk
www.ic.nhs.uk

The NHS Information Centre
for health and social care
1 Trevelyan Square
Boar Lane
Leeds
LS1 6AE